124 results on '"Lago T"'
Search Results
2. 1677P Risk factors predicting immune checkpoint inhibitors (ICIs) toxicity using machine learning computer algorithm
- Author
-
Holland, R., primary, Miron, K., additional, Goshen-Lago, T., additional, Gordon, N., additional, Zer, A., additional, and Ben-Aharon, I., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Non-classic effects in stochastic gene expression: P03-002-SH
- Author
-
Lago, T. T.
- Published
- 2015
4. Elective cancer surgery in COVID-19–Free surgical pathways during the SARS-cov-2 pandemic: An international, multicenter, comparative cohort study
- Author
-
James C Glasbey, Dmitri Nepogodiev, Joana Ff Simoes, Omar Omar, Elizabeth Li, Mary L Venn, Mohammad Abou Chaar, Vita Capizzi, Daoud Chaudhry, Anant Desai, Jonathan G Edwards, Jonathan P Evans, Marco Fiore, Jose Flavio Videria, Samuel J Ford, Ian Ganyli, Ewen A Griffiths, Rohan R Gujjuri, Angelos G Kolias, Haytham Ma Kaafarani, Ana Minaya-Bravo, Siobhan C McKay, Helen M Mohan, Keith Roberts, Carlos San Miguel-Méndez, Peter Pockney, Richard Shaw, Neil J Smart, Grant D Stewart, Sudha Sundar, Raghavan Vidya, Aneel A Bhangu, James C Glasbey, Omar Omar, Aneel A Bhangu, Kwabena Siaw-Acheampong, Ruth A Benson, Edward Bywater, Daoud Chaudhry, Brett E Dawson, Jonathan P Evans, James C Glasbey, Rohan R Gujjuri, Emily Heritage, Conor S Jones, Sivesh K Kamarajah, Chetan Khatri, Rachel A Khaw, James M Keatley, Andrew Knight, Samuel Lawday, Elizabeth Li, Harvinder S Mann, Ella J Marson, Kenneth A McLean, Siobhan C McKay, Emily C Mills, Dmitri Nepogodiev, Gianluca Pellino, Maria Picciochi, Elliott H Taylor, Abhinav Tiwari, Joana Ff Simoes, Isobel M Trout, Mary L Venn, Richard Jw Wilkin, Aneel A Bhangu, James C Glasbey, Neil J Smart, Ana Minaya-Bravo, Jonathan P Evans, Gaetano Gallo, Susan Moug, Francesco Pata, Peter Pockney, Salomone Di Saverio, Abigail Vallance, Dale Vimalchandran, Ewen A Griffiths, Sivesh K Kamarajah, Richard Pt Evans, Philip Townend, Keith Roberts, Siobhan McKay, John Isaac, Sohei Satoi, John Edwards, Aman S Coonar, Adrian Marchbank, Edward J Caruana, Georgia R Layton, Akshay Patel, Alessandro Brunelli, Samuel Ford, Anant Desai, Alessandro Gronchi, Marco Fiore, Max Almond, Fabio Tirotta, Sinziana Dumitra, Angelos Kolias, Stephen J Price, Daniel M Fountain, Michael D Jenkinson, Peter Hutchinson, Hani J Marcus, Rory J Piper, Laura Lippa, Franco Servadei, Ignatius Esene, Christian Freyschlag, Iuri Neville, Gail Rosseau, Karl Schaller, Andreas K Demetriades, Faith Robertson, Alex Alamri, Richard Shaw, Andrew G Schache, Stuart C Winter, Michael Ho, Paul Nankivell, Juan Rey Biel, Martin Batstone, Ian Ganly, Raghavan Vidya, Alex Wilkins, Jagdeep K Singh, Dinesh Thekinkattil, Sudha Sundar, Christina Fotopoulou, Elaine Leung, Tabassum Khan, Luis Chiva, Jalid Sehouli, Anna Fagotti, Paul Cohen, Murat Gutelkin, Rahel Ghebre, Thomas Konney, Rene Pareja, Rob Bristow, Sean Dowdy, T S Shylasree, R Kottayasamy Seenivasagam, Joe Ng, Keiiji Fujiwara, Grant D Stewart, Benjamin Lamb, Krishna Narahari, Alan McNeill, Alexandra Colquhoun, John McGrath, Steve Bromage, Ravi Barod, Veeru Kasivisvanathan, Tobias Klatte, Joana Ff Simoes, Tom Ef Abbott, Sadi Abukhalaf, Michel Adamina, Adesoji O Ademuyiwa, Arnav Agarwal, Murat Akkulak, Ehab Alameer, Derek Alderson, Felix Alakaloko, Markus Albertsmeiers, Osaid Alser, Muhammad Alshaar, Sattar Alshryda, Alexis P Arnaud, Knut Magne Augestad, Faris Ayasra, José Azevedo, Brittany K Bankhead-Kendall, Emma Barlow, David Beard, Ruth A Benson, Ruth Blanco-Colino, Amanpreet Brar, Ana Minaya-Bravo, Kerry A Breen, Chris Bretherton, Igor Lima Buarque, Joshua Burke, Edward J Caruana, Mohammad Chaar, Sohini Chakrabortee, Peter Christensen, Daniel Cox, Moises Cukier, Miguel F Cunha, Giana H Davidson, Anant Desai, Salomone Di Saverio, Thomas M Drake, John G Edwards, Muhammed Elhadi, Sameh Emile, Shebani Farik, Marco Fiore, J Edward Fitzgerald, Samuel Ford, Tatiana Garmanova, Gaetano Gallo, Dhruv Ghosh, Gustavo Mendonça Ataíde Gomes, Gustavo Grecinos, Ewen A Griffiths, Madalegna GrÜndl, Constantine Halkias, Ewen M Harrison, Intisar Hisham, Peter J Hutchinson, Shelley Hwang, Arda Isik, Michael D Jenkinson, Pascal Jonker, Haytham Ma Kaafarani, Debby Keller, Angelos Kolias, Schelto Kruijff, Ismail Lawani, Hans Lederhuber, Sezai Leventoglu, Andrey Litvin, Andrew Loehrer, Markus W Löffler, Maria Aguilera Lorena, Maria Marta Modolo, Piotr Major, Janet Martin, Hassan N Mashbari, Dennis Mazingi, Symeon Metallidis, Ana Minaya-Bravo, Helen M Mohan, Rachel Moore, David Moszkowicz, Susan Moug, Joshua S Ng-Kamstra, Mayaba Maimbo, Ionut Negoi, Milagros Niquen, Faustin Ntirenganya, Maricarmen Olivos, Kacimi Oussama, Oumaima Outani, Marie Dione Parreno-Sacdalanm, Francesco Pata, Carlos Jose Perez Rivera, Thomas D Pinkney, Willemijn van der Plas, Peter Pockney, Ahmad Qureshi, Dejan Radenkovic, Antonio Ramos-De la Medina, Keith Roberts, April C Roslani, Martin Rutegård, Juan José Segura-Sampedro, Irène Santos, Sohei Satoi, Raza Sayyed, Andrew Schache, Andreas A Schnitzbauer, Justina O Seyi-Olajide, Neil Sharma, Richard Shaw, Sebastian Shu, Kjetil Soreide, Antonino Spinelli, Grant D Stewart, Malin Sund, Sudha Sundar, Stephen Tabiri, Philip Townend, Georgios Tsoulfas, Gabrielle H van Ramshorst, Raghavan Vidya, Dale Vimalachandran, Oliver J Warren, Duane Wedderburn, Naomi Wright, C Allemand, L Boccalatte, M Figari, M Lamm, J Larrañaga, C Marchitelli, F Noll, D Odetto, M Perrotta, J Saadi, L Zamora, C Alurralde, E L Caram, D Eskinazi, J P Mendoza, M Usandivaras, R Badra, A Esteban, J S García, P M García, J I Gerchunoff, S M Lucchini, M A NIgra, L Vargas, T Hovhannisyan, A Stepanyan, T Gould, R Gourlay, B Griffiths, S Gananadha, M McLaren, J Cecire, N Joshi, S Salindera, A Sutherland, J H Ahn, G Charlton, S Chen, N Gauri, R Hayhurst, S Jang, F Jia, C Mulligan, W Yang, G Ye, H Zhang, M Ballal, D Gibson, D Hayne, J Moss, T Richards, P Viswambaram, U G Vo, J Bennetts, T Bright, M Brooke-Smith, R Fong, B Gricks, Y H Lam, B S Ong, M Szpytma, D Watson, K Bagraith, S Caird, E Chan, C Dawson, D Ho, E Jeyarajan, S Jordan, A Lim, G J Nolan, A Oar, D Parker, H Puhalla, A Quennell, L Rutherford, P Townend, M Von Papen, M Wullschleger, A Blatt, D Cope, N Egoroff, M Fenton, J Gani, N Lott, P Pockney, N Shugg, M Elliott, D Phung, D Phan, D Townend, C Bong, J Gundara, A Frankel, S Bowman, G R Guerra, J Bolt, K Buddingh, N N Dudi-Venkata, S Jog, H M Kroon, T Sammour, R Smith, C Stranz, M Batstone, K Lah, W McGahan, D Mitchell, A Morton, A Pearce, M Roberts, G Sheahan, B Swinson, N Alam, S Banting, L Chong, P Choong, S Clatworthy, D Foley, A Fox, M W Hii, B Knowles, J Mack, M Read, A Rowcroft, S Ward, G Wright, M Lanner, I Königsrainer, M Bauer, C Freyschlag, M Kafka, F Messner, D Öfner, I Tsibulak, K Emmanuel, M Grechenig, R Gruber, M Harald, L Öhlberger, J Presl, A Wimmer, I Namazov, E Samadov, D Barker, R Boyce, S Corbin, A Doyle, A Eastmond, R Gill, A Haynes, S Millar, M O'Shea, G Padmore, N Paquette, E Phillips, S St John, K Walkes, N Flamey, P Pattyn, W Oosterlinck, J Van den Eynde, R Van den Eynde, A Gatti, C Nardi, R Oliva, R De Cicco, I Cecconello, P Gregorio, L Pontual Lima, U Ribeiro Junior, F Takeda, R M Terra, M Sokolov, B Kidane, S Srinathan, M Boutros, N Caminsky, G Ghitulescu, G Jamjoum, J Moon, J Pelletier, T Vanounou, S Wong, M Boutros, S Dumitra, A Kouyoumdjian, B Johnston, C Russell, M Boutros, S Demyttenaere, R Garfinkle, J Abou-Khalil, C Nessim, J Stevenson, F Heredia, A Almeciga, A Fletcher, A Merchan, L O Puentes, J Mendoza Quevedo, G Bacic, D Karlovic, D Krsul, M Zelic, I Luksic, M Mamic, B Bakmaz, I Coza, E Dijan, Z Katusic, J Mihanovic, I Rakvin, K Frantzeskou, N Gouvas, G Kokkinos, P Papatheodorou, I Pozotou, O Stavrinidou, A Yiallourou, L Martinek, M Skrovina, I Szubota, J Žatecký, V Javurkova, J Klat, T Avlund, P Christensen, J L Harbjerg, L H Iversen, D W Kjaer, Hø Kristensen, M Mekhael, A L Ebbehøj, P Krarup, N Schlesinger, H Smith, A Abdelsamed, A Y Azzam, H Salem, A Seleim, A Abdelmajeed, M Abdou, N E Abosamak, M Al Sayed, F Ashoush, R Atta, E Elazzazy, M Elhoseiny, M Elnemr, M S Elqasabi, M E Elsayed Hewalla, I Elsherbini, E Essam, M Eweda, I Ghallab, E Hassan, M Ibrahim, M Metwalli, M Mourad, M S Qatora, M Ragab, A Sabry, H Saifeldin, M Saleh Mesbah Mohamed Elkaffas, A Samih, A Samir Abdelaal, S Shehata, K Shenit, D Attia, N Kamal, N Osman, A M Abbas, Has Abd Elazeem, M M Abdelkarem, S Alaa, A K Ali, A Ayman, M G Azizeldine, H Elkhayat, S M Elghazaly, F A Monib, M A Nageh, M M Saad, M Salah, M Shahine, E A Yousof, A Youssef, A Eldaly, M ElFiky, A Nabil, G Amira, I Sallam, M Sherief, A Sherif, A Abdelrahman, H Aboulkassem, G Ghaly, R Hamdy, A Morsi, H Salem, G Sherif, H Abdeldayem, I Abdelkader Salama, M Balabel, Y Fayed, A E Sherif, D Bekele, J Kauppila, E Sarjanoja, O Helminen, H Huhta, J H Kauppila, C Beyrne, L Jouffret, L Lugans, L Marie-Macron, E Chouillard, B De Simone, J Bettoni, S Dakpé, B Devauchelle, N Lavagen, S Testelin, S Boucher, R Breheret, A Gueutier, A Kahn, J KÜn-Darbois, A Barrabe, Z Lakkis, A Louvrier, S Manfredelli, P Mathieu, A Chebaro, V Drubay, M El Amrani, C Eveno, K Lecolle, G Legault, L Martin, G Piessen, F R Pruvot, S Truant, P Zerbib, Q Ballouhey, B Barrat, J Laloze, H Salle, A Taibi, J Usseglio, D Bergeat, A Merdrignac, Roy B Le, L O Perotto, A Scalabre, A Aimé, A Ezanno, B Malgras, P Bouche, S Tzedakis, E Cotte, O Glehen, V Kepenekian, J Lifante, G Passot, A D'Urso, E Felli, D Mutter, P Pessaux, B Seeliger, J Bardet, R Berry, G Boddaert, S Bonnet, E Brian, C Denet, D Fuks, D Gossot, M Grigoroiu, A Laforest, Y Levy-Zauberman, C Louis-Sylvestre, A Moumen, G Pourcher, A Seguin-Givelet, E Tribillon, E Duchalais, F Espitalier, C Ferron, O Malard, U Bork, M Distler, J Fritzmann, J Kirchberg, C Praetorius, C Riediger, J Weitz, T Welsch, P Wimberger, K Beyer, C Kamphues, J Lauscher, F N Loch, C Schineis, M Albertsmeier, M Angele, A Kappenberger, H Niess, T Schiergens, J Werner, R Becker, J Jonescheit, I Pergolini, D Reim, C Boeker, I Hakami, J Mall, P Liokatis, W Smolka, K Nowak, T Reinhard, F Hölzle, A Modabber, P Winnand, M Knitschke, P Kauffmann, S Wolfer, J Kleeff, K Lorenz, C Michalski, U Ronellenfitsch, R Schneider, E Bertolani, A Königsrainer, M W Löffler, M Quante, C Steidle, L ÜberrÜck, C Yurttas, C S Betz, J Bewarder, A Böttcher, S Burg, C Busch, M Gosau, A Heuer, J Izbicki, T O Klatte, D Koenig, N Moeckelmann, C Nitschke, M Priemel, R Smeets, U Speth, S Thole, F G Uzunoglu, T Vollkommer, N Zeller, M J Battista, K Gillen, A Hasenburg, S Krajnak, V Linz, R Schwab, K Angelou, D Haidopoulos, A Rodolakis, P Antonakis, K Bramis, L Chardalias, I Contis, N Dafnios, D Dellaportas, G Fragulidis, A Gklavas, M Konstadoulakis, N Memos, I Papaconstantinou, A Polydorou, T Theodosopoulos, A Vezakis, M I Antonopoulou, D K Manatakis, N Tasis, N Arkadopoulos, N Danias, P Economopoulou, P Kokoropoulos, A Larentzakis, N Michalopoulos, J Selmani, T Sidiropoulos, V Tsaousis, P Vassiliu, K Bouchagier, S Klimopoulos, D Paspaliari, G Stylianidis, K Baxevanidou, K Bouliaris, P Chatzikomnitsa, M Efthimiou, A Giaglaras, C Kalfountzos, G Koukoulis, A M Ntziovara, K Petropoulos, K Soulikia, I Tsiamalou, K Zervas, S Zourntou, I Baloyiannis, A Diamantis, E Gkrinia, J Hajiioannou, C Korais, O Koukoura, K Perivoliotis, A Saratziotis, C Skoulakis, D Symeonidis, K Tepetes, G Tzovaras, D Zacharoulis, V Alexoudi, K Antoniades, I Astreidis, P Christidis, D Deligiannidis, T Grivas, O Ioannidis, I Kalaitsidou, L Loutzidou, A Mantevas, D Michailidou, K Paraskevopoulos, S Politis, A Stavroglou, D Tatsis, I Tilaveridis, K Vahtsevanos, G Venetis, I Karaitianos, T Tsirlis, A Charalabopoulos, T Liakakos, E Mpaili, D Schizas, E Spartalis, A Syllaios, C Zografos, C Anthoulakis, C Christou, V Papadopoulos, A Tooulias, D Tsolakidis, G Tsoulfas, D Zouzoulas, E Athanasakis, E Chrysos, J Tsiaoussis, S Xenaki, E Xynos, K Futaba, M F Ho, S F Hon, Twc Mak, Ssm Ng, C C Foo, B Banky, N Suszták, M Aremu, A Canas-Martinez, O Cullivan, C Murphy, P Owens, L Pickett, L Akmenkalne, J Byrne, M Corrigan, C Cullinane, A Daly, C Fleming, P Jordan, S Killeen, N Lynch, A McCarthy, H Mustafa, S O'Brien, P O'Leary, Was Syed, L Vernon, D Callanan, L Huang, A Ionescu, P Sheahan, I Balasubramanian, M Boland, K Conlon, D Evoy, N Fearon, T Gallagher, J Geraghty, H Heneghan, N Kennedy, D Maguire, D McCartan, E W McDermott, R S Prichard, D Winter, D Alazawi, C Barry, T Boyle, W Butt, E M Connolly, N Donlon, C Donohue, B A Fahey, R Farrell, C Fitzgerald, J Kinsella, J O Larkin, P Lennon, P J Maguire, P Mccormick, B J Mehigan, H Mohan, T Nugent, H O'Sullivan, N Ravi, J V Reynolds, A Rogers, P Shokuhi, J Smith, L A Smith, C Timon, Y Bashir, G Bass, T Connelly, B Creavin, H Earley, J A Elliott, A Gillis, D Kavanagh, P Neary, J O'riordan, I S Reynolds, D Rice, P Ridgway, M Umair, M Whelan, P Carroll, C Collins, K Corless, L Finnegan, A Fowler, A Hogan, M Kerin, A Lowery, P McAnena, K McKevitt, K Nizami, É Ryan, A Samy, J C Coffey, R Cunningham, M Devine, D Nally, C Peirce, S Tormey, N Hardy, P Neary, S O'Malley, M Ryan, S Macina, N M Mariani, E Opocher, A Pisani Ceretti, F Ferrari, F Odicino, E Sartori, C Cotsoglou, S Granieri, F Bianco, A Camillo, M Colledan, S Tornese, M F Zambelli, G Bissolotti, S Fusetti, F Lemma, M V Marino, A Mirabella, G Vaccarella, C Agostini, G Alemanno, I Bartolini, C Bergamini, A Bruscino, C Checcucci, R De Vincenti, A Di Bella, M Fambrini, L Fortuna, G Maltinti, P Muiesan, F Petraglia, P Prosperi, M N Ringressi, M Risaliti, F Sorbi, A Taddei, R Tucci, C Bassi, L Bortolasi, T Campagnaro, L Casetti, M De Pastena, A Esposito, M Fontana, A Guglielmi, L Landoni, G Malleo, G Marchegiani, S Nobile, S Paiella, C Pedrazzani, S Rattizzato, A Ruzzenente, R Salvia, G Turri, M Tuveri, P Bellora, G D'Aloisio, M Ferrari, E Francone, S Gentilli, H Nikaj, M Bianchini, M Chiarugi, F Coccolini, G Di Franco, N Furbetta, D Gianardi, S Guadagni, L Morelli, M Palmeri, D Tartaglia, G Anania, P Carcoforo, M Chiozza, A De Troia, M Koleva Radica, M Portinari, M G Sibilla, A Urbani, N Fabbri, C V Feo, S Gennari, S Parini, E Righini, L Ampollini, L Bellanti, M Bergonzani, G Bertoli, G Bocchialini, G D'Angelo, D Lanfranco, L Musini, T Poli, G P Santoro, A Varazzani, L Aguzzoli, G Borgonovo, C Castro Ruiz, S Coiro, G Falco, V D Mandato, V Mastrofilippo, M T Montella, V Annessi, M Zizzo, U Grossi, S Novello, M Romano, S Rossi, G Zanus, G Esposito, F Frongia, A Pisanu, M Podda, C Belluco, A Lauretta, G Montori, L Moras, M Olivieri, F Bussu, A G Carta, M L Cossu, P Cottu, A Fancellu, C F Feo, G C Ginesu, G Giuliani, M Madonia, T Perra, A Piras, A Porcu, D Rizzo, A M Scanu, A Tedde, M Tedde, P Delrio, D Rega, G Badalamenti, G Campisi, A Cordova, M Franza, G Maniaci, G Rinaldi, F Toia, M Calabrò, F Farnesi, E G Lunghi, A Muratore, N S Pipitone Federico, F Bàmbina, G D'Andrea, P Familiari, V Picotti, G De Palma, G Luglio, G Pagano, F P Tropeano, L Baldari, G A Beltramini, L Boni, E Cassinotti, A Gianni, L Pignataro, S Torretta, C Abatini, M Baia, D Biasoni, G Bogani, P Cadenelli, V Capizzi, Spb Cioffi, D Citterio, L V Comini, M Cosimelli, M Fiore, S Folli, M Gennaro, L Giannini, A Gronchi, M Guaglio, A Macchi, F Martinelli, V Mazzaferro, A Mosca, S Pasquali, C Piazza, F Raspagliesi, L Rolli, R Salvioni, G Sarpietro, C Sarre, L Sorrentino, A Agnes, S Alfieri, F Belia, A Biondi, V Cozza, A D'Amore, D D'Ugo, V De Simone, A Fagotti, G Gasparini, L Gordini, F Litta, C P Lombardi, L Lorenzon, A A Marra, F Marzi, A Moro, A Parello, E Perrone, R Persiani, C Ratto, F Rosa, G Saponaro, G Scambia, O Scrima, G Sganga, R Tudisco, A Belli, V Granata, F Izzo, R Palaia, R Patrone, F M Carrano, M M Carvello, A De Virgilio, F Di Candido, F Ferreli, F Gaino, G Mercante, V Rossi, A Spinelli, G Spriano, D M Donati, T Frisoni, E Palmerini, A Aprile, F Barra, P Batistotti, S Ferrero, P Fregatti, S Scabini, M Sparavigna, E Asti, D Bernardi, L Bonavina, A Lovece, L Adamoli, M Ansarin, S Cenciarelli, F Chu, R De Berardinis, U Fumagalli Romario, F Mastrilli, G Pietrobon, M Tagliabue, E Badellino, A Ferrero, R Massobrio, A De Manzoni Garberini, P Federico, P Maida, E Marra, G Marte, A Petrillo, T Tammaro, A Tufo, M Berselli, G Borroni, E Cocozza, L Conti, M Desio, L Livraghi, V Quintodei, A Rizzi, A Zullo, C Baldi, C Corbellini, G M Sampietro, P Cellerino, E Baldini, P Capelli, L Conti, S M Isolani, M Ribolla, A Bondurri, F Colombo, L Ferrario, C Guerci, A Maffioli, T Armao, M Ballabio, P Bisagni, A Gagliano, M Longhi, M Madonini, P PizziCni, A M Baietti, M Biasini, P Maremonti, F Neri, G M Prucher, S Ricci, F Ruggiero, A G Zarabini, R Barmasse, S Mochet, L Morelli, A Usai, F Bianco, P Incollingo, S Mancini, L Marino Cosentino, A Sagnotta, R Fruscio, T Grassi, L C Nespoli, N Tamini, A Anastasi, B Bartalucci, A Bellacci, G Canonico, L Capezzuoli, C Di Martino, P Ipponi, C Linari, M Montelatici, T Nelli, G Spagni, L Tirloni, A Vitali, E Abate, M Casati, T Casiraghi, L Laface, M Schiavo, A Arminio, A Cotoia, V Lizzi, F Vovola, R Vergari, S D'Ugo, N Depalma, M G Spampinato, P Bartolucci, G Brachini, P Bruzzaniti, A Chiappini, V Chiarella, F Ciccarone, P M Cicerchia, B Cirillo, G De Toma, A Di Bartolomeo, E Fiori, G B Fonsi, G Franco, A Frati, M Giugliano, I Iannone, F La Torre, P Lapolla, C Leonardo, G Marruzzo, S Meneghini, A Mingoli, D Ribuffo, M Salvati, A Santoro, P Sapienza, A K Scafa, L Simonelli, M Zambon, G T Capolupo, F Carannante, M Caricato, G Mascianà, E Mazzotta, A Gattolin, M Migliore, R Rimonda, D Sasia, E Travaglio, M Cervellera, A Gori, L Sartarelli, V Tonini, M Giacometti, S Zonta, A Chessa, A Fiorini, C Norcini, G Colletti, M Confalonieri, A Costanzi, C Frattaruolo, G Mari, M Monteleone, A Bandiera, L Bocciolone, G Bonavina, M Candiani, G Candotti, P De Nardi, F Gagliardi, M Medone, P Mortini, G Negri, P Parise, M Piloni, P Sileri, A Vignali, A Belvedere, P Bernante, P Bertoglio, S Boussedra, E Brunocilla, R Cipriani, G Cisternino, E De Crescenzo, P De Iaco, G Dondi, F Frio, E Jovine, F Mineo Bianchi, J Neri, D Parlanti, A M Perrone, A P Pezzuto, M Pignatti, V Pinto, G Poggioli, M Ravaioli, M Rottoli, R Schiavina, M Serenari, M Serra, P Solli, M Taffurelli, M Tanzanu, M Tesei, T Violante, S Zanotti, F Borghi, D Cianflocca, S Di Maria Grimaldi, D Donati, E Gelarda, P Geretto, G Giraudo, M C Giuffrida, A Marano, S Palagi, L Pellegrino, C Peluso, V Testa, F Agresta, D Prando, M Zese, F Aquila, C Gambacciani, L Lippa, F Pieri, O S Santonocito, G Armatura, G Bertelli, A Frena, P Marinello, F Notte, S Patauner, G Scotton, S F Fulginiti, G Gallo, G Sammarco, G Vescio, P Balercia, L Catarzi, G Consorti, F Di Marzo, T Fontana, H Daiko, M Ishikawa, K Ishiyama, S Iwata, K Kanematsu, Y Kanemitsu, T Kato, A Kawai, E Kobayashi, M Kobayashi Kato, K Moritani, F Nakatani, J Oguma, Y Tanase, M Uno, M Al Abdallah, F Ayasra, Y Ayasra, A Qasem, F J Abu Za'nouneh, T Fahmawee, A Hmedat, A Ibrahim, K Obeidat, S Abdel Al, R Abdel Jalil, M K Abou Chaar, M Al-Masri, H Al-Najjar, F Alawneh, O Alsaraireh, M Elayyan, R Ghanem, I Lataifeh, G Z Alkadeeki, F S Al Maadany, N Aldokali, O Senossi, M T Subhi, D Burgan, E Kamoka, A I Kilani, A Salamah, M Salem, A Shuwayyah, E Abdulwahed, E Alshareea, N Aribi, S Aribi, M Biala, R Ghamgh, M Morgom, Z Aldayri, I Ellojli, A Kredan, S Bradulskis, E Dainius, E Kubiliute, J Kutkevicius, A Parseliunas, A Subocius, D Venskutonis, F Rasoaherinomenjanahary, J B Razafindrahita, L H Samison, E C Ong, K H Hamdan, M R Ibrahim, J A Tan, M R Thanapal, N Amin Sahid, F Hayati, J Jayasilan, R K Sriram, S Subramaniam, A Che Jusoh, A H Hussain, A S Mohamed Sidek, M F Mohd Yunus, J Y Soh, Mpk Wong, A D Zakaria, Z Zakaria, A Fadzli, N Q Fathi, P S Koh, Y T Liew, A C Roslani, C Y Tang, L Y Teoh, W J Wong, A S Yahaya, M R Alvarez, R Arrangoiz, F Cordera, M A De la Rosa Abaroa, A Gómez-Pedraza, R Hernandez, A Maffuz-Aziz, J A Posada, F C Becerra García, A Alfaro-Goldaracena, G A Buerba, R A Castillejos-Molina, C Chan, I Dominguez-Rosado, H Medina-Franco, Má Mercado, M Oropeza-Aguilar, E Peña Gómez Portugal, O E Posadas-Trujillo, F Rodriguez-Covarrubias, N Salgado-Nesme, C Sarre, M Vilatoba, Y Arkha, H Bechri, A El Ouahabi, M Y Oudrhiri, F Derkaoui Hassani, N El Abbadi, L Amrani, Z H Belkhadir, A Benkabbou, O Chakib, B El Ahmadi, Y El Bouazizi, H Essangri, A Ghannam, A M Majbar, R Mohsine, A Souadka, R Hompes, E M Meima-van Praag, Ajm Pronk, S Sharabiany, B Grotenhuis, L Hartveld, S Reijers, W Van Houdt, J Baaij, M Bolster-van Eenennaam, M De Graaff, D Sloothaak, P Van Duijvendijk, L Posma-Bouman, T Derksen, J Franken, S Oosterling, R De Bree, J Konsten, M Van Heinsbergen, L Fidelis, T T Sholadoye, M A Tolani, J Olaogun, I K Egbuchulem, T A Lawal, O Ogundoyin, D I Olulana, L Abdur-Rahman, A Adeyeye, I Aremu, J Bello, O Olasehinde, A Popoola, J Massoud, R Massoud, T M Sorour, A Jamal, A A Kerawala, A S Memon, R Nafees Ahmed, L Rai, B Ayub, N Hassan, R S Martins, P Ramesh, R Sayyed, U Butt, M Kashif, M Kashif, W H Khan, A Qureshi, M Umar, M Waris Farooka, T Wasim, A Ayubi, I Rashid, S H Waqar, G M Falcon, R Robles, R Jocson, C Teh, P Major, M Bobinski, J Kotarski, K Rasoul-Pelinska, C Azevedo, D Machado, F Mendes, X De Sousa, U Fernandes, C Ferreira, G Guidi, C Leal, A Marçal, R Marques, D Martins, A Melo, N Tenreiro, R Vaz Pereira, B Vieira, J I Almeida, T Correia de Sá, Mjma Costa, V Fernandes, I Ferraz, C G Gil, C Lima da Silva, L Lopes, N Machado, J Marialva, M Nunes Coelho, J Pedro, C Pereira, R Reis, A Ribeiro, R Santos, P Saraiva, R Silva, F Tavares, M Teixeira, A C Almeida, M J Amaral, R Andrade, R Athayde Nemésio, D Breda, C Camacho, C Canhoto, M Colino, S Correia, M Costa, J De Barros, A L De Oliveira López, M Duque, S Garrido, P Guerreiro, A Guimarães, A Lázaro, C Lopes, R Martins, O Nogueira, A Oliveira, J M Oliveira, M Rodrigues, A Ruivo, E Santos, M Silva, J Simões, A Valente da Costa, A Almeida, S Cavaleiro, V Devezas, C S Faria, F Jácome, M Magalhães Maia, J Nogueiro, A Pereira, A Pereira-Neves, T Pina-Vaz, H Santos-Sousa, H Silveira, S Vaz, P Vieira, A Gomes da Costa, I Lobo Antunes, J Pinto, A Tojal, N Cardoso, P Cardoso, J C Domingues, P Henriques, M I Manso, G Martins Dos Santos, R Martins, H Morais, R Pereira, T Revez, R Ribeiro, V I Ribeiro, A Soares, S Sousa, J Teixeira, E Amorim, V H Baptista, B Cunha MFDias, A Fazenda, J P Melo Neves, F Policarpo, I I Sampaio da Nóvoa Gomes Miguel, D Veiga, A K Andrade, J P Bandovas, N Borges, A Branquinho, B Chumbinho, J Correia, H Fidalgo, I Figueiredo de Barros, S Frade, J Gomes, J Maciel, S Pina, A Rodrigues, N Silva, I Silveira Nunes, R Sousa, J Ascensão, P Azevedo, B Costeira, C Cunha, R Garrido, H Gomes, I Lourenço, G Mendinhos, P Miranda, A Nobre Pinto, M Peralta Ferreira, J Ribeiro, L Rio Rodrigues, M Sousa Fernandes, J Azevedo, D Galvão, A C Soares, A Vieira, B Vieira, B Patrício, Pmdd Santos, A C Vieira Paiva Lopes, R Cunha, A Faustino, A Freitas, J R Martins ABMendes, R Parreira, J Rosa, M Teves, A Abreu da Silva, M Claro, D Costa Santos, A C Deus, J V Grilo, F Borges, J Corte Real, S Henriques, M J Lima, P Matos Costa, F Brito da Silva, A Caiado, F Fonseca, M Ângelo, J M Baiao, D Martins Jordão, T Vieira Caroço, J Messias, A Millan, I Salgado, P Santos, C Baía, R Canotilho, A M Correia, A P Ferreira Pinto, M Peyroteo, J F Videira, P Escobar, M Maldonado Santiago, R Kassir, F Sauvat, C Bezede, A Chitul, E Ciofic, D Cristian, F Grama, L Pirtea, C Secosan, E Bonci, V Gata, S Titu, O Ginghina, N Iordache, R V Iosifescu, T Garmanova, E Kazachenko, D Markaryan, S Rodimov, P Tsarkov, I Tulina, Y Litvina, A Provozina, M Agapov, E Galliamov, V Kakotkin, V Kubyshkin, А Kamalov, M Alshahrani, F Alsharif, M Eskander, R Al Raddadi, S Majrashi, A Mashat, N Akeel, M Alharthi, M Aljiffry, M Basendowah, A Farsi, M Ghunaim, A Khoja, A Maghrabi, N Malibary, M Nassif, A Nawawi, A Saleem, A Samkari, N Trabulsi, S Al Awwad, M Alghamdi, T Alnumani, M Nasser, A Said Bayazeed, A Alhefdhi, O Almalik, A Alomair, N Alotaibi, F Alresaini, R Alsalamah, S Alsobhi, Z Mahasin, E Othman, S Velagapudi, S Ghedan, R Alharthi, S Awad, M I Sharara, S Abdelrahman, W Althobaiti, H Al Habes, A Alamri, S Alkarak, M Alqannas, M Alyami, M Alzamanan, D Cortés Guiral, A Elawad, O AlAamer, L Alriyees, N Alselaim, A Abdulkareem, A Ajlan, K Akkour, A Al-Habib, K Al-Khayal, A Alatar, A Alburakan, H Alhalal, B Alhassan, N Alhassan, O Alobeed, A Alsaif, F Alsaif, S Alshammari, I Alshaygy, M Barry, A Bin Nasser, T Bin Traiki, A Bokhari, S Elwatidy, H Helmi, A Madkhali, T Nouh, P D Rabah, A Zubaidi, I Paunovic, N Slijepcevic, L Aleksic, A Antic, G Barisic, M Ceranic, D Galun, Ž Grubac, J Jelenkovic, D Kecmanovic, S Kmezic, D Knezevic, Z Krivokapic, S Latincic, V Markovic, S Matic, M Miladinov, M Pavlov, I Pejovic, D Radenkovic, B Tadic, J Vasljevic, D Velickovic, M Zivanovic, M Perovic, L Srbinovic, S Andrijasevic, T Bozanovic, R Cerovic Popovic, M Dokic, T Janjic, K Jeremic, S Kadija, I Ladjevic Likic, L Mirkovic, S Pantovic, I Pilic, M Radojevic, A Stefanovic, S Vidakovic, Z Vilendecic, S Antic, D Dunderovic, D Jelovac, Z Jezdic, V Konstantinovic, B Kotlar, C Kuzmanovic, M Lazic, M Petrovic, F Popovic, A Pucar, M Romic, S Sumrak, V Vujanac, V Bascarevic, I Bogdanovic, D Grujicic, R Ilic, M Milicevic, F Milisavljevic, A Miljkovic, A Paunovic, V Scepanovic, A Stanimirovic, M Todorovic, A Jotic, J Milovanovic, A Trivic, U Bumbasirevic, Z Dzamic, B Kajmakovic, N Prijovic, M Zivkovic, M Buta, A Cvetkovic, I Djurisic, S Gacic, M Goran, Z Inic, N Jeftic, M Jevric, V Jokic, I Markovic, M Milanovic, S Nikolic, L Pejnovic, N Savkovic, I Spurnic, D Stevic, D Stojiljkovic, N Vucic, M Zegarac, A Karamarkovic, M Kenic, B Kovacevic, I Krdzic, V Milutinovic, C W Chan, B Lieske, B Gális, K Šimko, N Almgla, M Bernon, A Boutall, L Cairncross, A Herman, T Hilton, E Jonas, C Kloppers, F Malherbe, W Mugla, D Nel, S Rayamajhi, T Van Wyngaard, J Vogel, A M Castaño-Leon, J Delgado Fernandez, C Eiriz Fernandez, M Espino Segura-Illa, O Esteban Sinovas, D Garcia Perez, P Gomez, L Jimenez-Roldan, A Lagares, L Moreno-Gomez, I Paredes, A Pérez Núñez, G Sánchez Aniceto, M Santas, P Fernández Rodríguez, M Paniagua García Señorans, R Sanchez-Santos, V Vigorita, E Acrich, E Baena Sanfeliu, O Barrios, T Golda, C Santanach, M Serrano-Navidad, M Sorribas Grifell, R V Vives, D Escolà, A Jiménez, L Cayetano Paniagua, L Gómez Fernández, E Artigues, J C Bernal-Sprekelsen, J C Catalá Bauset, P Collera, L Diaz De, R Gobbo, R Farre Font, R Flores Clotet, C J Gómez Díaz, N Guàrdia, C A Guariglia, A Osorio, R Sanchez Jimenez, L Sanchon, C Soto Montesinos, B Albi Martin, J E García Villayzán, L Alonso-Lamberti, M Assaf, N Baeza Pintado, A Carabias, J García-Quijada, M A Huertas Fernandez, J Jimenez Miramón, V Jimenez, J M Jover, S A Landeo AgÜero, R Leon, M B Martín Salamanca, V Pérez Simón, S Ponce, J L Rodriguez, A Salazar, A Valle Rubio, H Aguado, I Aldecoa Ansorregui, R Bravo Infante, F B De Lacy, A Di Somma, B Díaz-Feijoo, J Enseñat Nora, N Fabregas, A Ferrés, B Gil Ibañez, J J Gonzalez Sanchez, I Gracia, J A Hoyos Castro, A M Lacy, C Langdon, D Momblán, X Morales, L Oleaga, A Otero, L Pedrosa, J Poblete Carrizo, L A Reyes Figueroa, P Roldan Ramos, J Rumia-Arboix, A I Tercero-Uribe, T E Topczewski, J Torales, A Torne, R Torné, V Turrado-Rodriguez, R Valero, S Valverde, R Anula, O Cano-Valderrama, M Del Campo Martín, L Díez-Valladares, I Domínguez, J Dziakova, M García Alonso, E García Romero, L Gómez Latorre, J M Muguerza, M J Pizarro, P Saez Carlin, C Sánchez Del Pueblo, A Sánchez-Pernaute, G Sanz Ortega, R Sanz-Lopez, A Torres, M Garcés-Albir, F Lopez, J Martín-Arévalo, D Moro-Valdezate, V Pla-Marti, J Beltrán de Heredia, B De Andrés Asenjo, T Gómez Sanz, C Jezieniecki, H Nuñez Del Barrio, F J Ortiz de Solórzano Aurusa, A Romero de Diego, M Ruiz Soriano, J Trujillo Díaz, A Vazquez Fernandez, P Lora-Cumplido, M V Sosa, E Gonzalez-Gonzalez, A M Minaya Bravo, N Alonso de la Fuente, M Cazador Labat, L Cecchini, C A Espinosa, M Jimenez Toscano, A López Campillo, G Mancebo, P Martorell, M Munarriz, E J Grau-Talens, B Martin-Perez, J A Benavides Buleje, M Carrasco Prats, P V Fernández, A Fernández-López, D García Escudero, V J García Porcel, V Garcia Soria, C Giménez Francés, F M González Valverde, E Gurrea, P López-Morales, A Marco Garrido, J A Martínez Alonso, E Medina, J M Muñoz Camarena, P A Parra Baños, E Peña Ros, M Ramirez Faraco, M Ruiz-Marín, C Sanchez Rodriguez, M Valero Soriano, M Estaire Gómez, Á Fernández Camuñas, E P Garcia Santos, E Jimenez Higuera, C Martínez-Pinedo, V Muñoz-Atienza, D Padilla-Valverde, R Picón Rodríguez, F J Redondo Calvo, S Sánchez-García, D Sanchez-Pelaez, R C Colombari, E Del Valle, M Fernández, P Lozano Lominchar, L Martín, C Rey Valcarcel, M A Steiner, M Tudela, J Zorrilla Ortúzar, F Alcaide Matas, J M García Pérez, P Troncoso Pereira, I Mora-Guzmán, M Abellán, M Achalandabaso Boira, R Jorba, R Memba Ikuga, C Olona, R Sales Mallafré, P Cavallé Busquets, Mgp Gavalda Pellice, J Salinas Peña, E J Aragon Achig, L Barbier, P Caja Vivancos, A Gainza, J J García Gutierrez, G Mallabiabarrena Ormaechea, H Marín, P Martin Playa, I Melchor Corcóstegui, M Prieto Calvo, A Rodriguez Fraga, I Villalabeitia Ateca, U De Andres Olabarria, M Durán Ballesteros, F J Fernández Pablos, F J Ibáãez-Aguirre, A Sanz Larrainzar, B Ugarte-Sierra, Á De la Hoz Rodríguez, M Di Martino, J García Septiem, E Martin-Perez, J L Muñoz de Nova, P Calvo Espino, P Guillamot Ruano, L Colao García, D Díaz Pérez, E Esteban Agustí, P Galindo Jara, M Gutierrez Samaniego, M A Hernandez Bartolome, J Serrano González, A Alonso Poza, B Diéguez, M García-Conde, M Hernández-García, M Losada, C M Chiesa-Estomba, Já González García, E Larruscain, J A Sistiaga-Suárez, E Alvarez, N Chavarrias, L Frías, V García Pineda, A Gegúndez Simón, S Gortázar, M Gracia, J Guevara, A Hernández Gutierrez, A Loayza, D T María Dolores, C Martí, M Melendez, E Moreno-Palacios, Y Perez, M I Prieto Nieto, P Ramos-Martín, I Rubio-Perez, J Saavedra, J I Sanchez-Mendez, J Siegrist Ridruejo, A Urbieta, I Zapardiel, M Cantalejo Diaz, Mdc De Miguel Ardevines, V Duque-Mallén, I Gascon Ferrer, M T González-Nicolás Trébol, C Gracia-Roche, M Herrero Lopez, U M Jariod Ferrer, A Lanzon, A Martinez German, M Matute, C Redondo, N Sánchez Fuentes, M Sánchez-Rubio, M S Santero-Ramirez, S Saudí, M V Simón Sanz, T Uson-Bouthelier, A Blazquez Martin, M Diez Alonso, E García Rico, E Garcia-Loarte Gomez, F Garcia-Moreno Nisa, A Gutierrez Calvo, P Hernandez, I Lasa, F Mendoza-Moreno, N Morales Palacios, E Ovejero Merino, C Vera Mansilla, F Acebes García, M Bailón, A D Bueno Cañones, E Choolani Bhojwani, P Marcos-Santos, T Miguel, D Pacheco Sánchez, B Pérez-Saborido, J Sanchez Gonzalez, F J Tejero-Pintor, F Alconchel, A Conesa, J Gil Martínez, A I Gutiérrez Fernández, A Lopez Abad, T Nicolás-López, P Ramirez Romero, M J Roca Calvo, K Rodrigues, J J Ruiz Manzanera, A I Soriano, A Cano, L Capitan-Morales, J Cintas Catena, J Gomez-Rosado, F Oliva Mompean, M A Pérez Sánchez, F D Río Lafuente, C Torres Arcos, J Valdes-Hernandez, H Cholewa, S Domingo, M Frasson, V Lago, T Marina Martin, C Martínez Chicote, J Sancho-Muriel, A Landaluce-Olavarria, D Lecumberri, A Abad Gurumeta, A Abad-Motos, E Martínez-Hurtado, J Ripollés-Melchor, A Ruiz Escobar, A Cuadrado-García, L Garcia-Sancho Tellez, J Heras Aznar, P Maté, I Ortega Vázquez, A L Picardo, J A Rojo López, F Sanchez Cabezudo Noguera, D Serralta de Colsa, J Anchuelo Latorre, C Cagigas Fernandez, R Caiña Ruiz, M Gomez Ruiz, F Hernanz, J Jimeno Fraile, P Martínez-Pérez, C Poch, S Santarrufina Martinez, V Valbuena Jabares, C Moliner-Sánchez, L Pingarron-Martin, J Rey-Biel, I Ruiz Martin, J L Blas Laina, B Cros, J Escartin, J Garcia Egea, A Nogués, I Talal El-Abur, C Yánez, E P Cagigal Ortega, I Cervera, P Díaz Peña, Gdcr Elena, D Enjuto, P Fernández Bernabé, R Garcés García, J Gonzalez, I Hernández, N Herrera-Merino, M Marqueta De Salas, P Martinez Pascual, M Perez Gonzalez, A Ramos Bonilla, L Rodríguez Gómez, C Bescós, R Blanco-Colino, I Brana, B Caimari, A De Pablo García-Cuenca, F Duran-Valles, E Espin-Basany, J Giralt Lóez de Sagredo, J Pamias, G Pellino, N Prat, R Pujol Pina, M Saez Barba, A Arulanantham, Gbk Bandara, U Jayarajah, S Ravindrakumar, V S Rodrigo, S Srishankar, A A Ali Karar, P Elbe, E K Lindqvist, H Taflin, A Älgå, G Heinius, M Nordberg, E Pieniowski, I Gkekas, N Löfgren, M Rutegård, M Sund, M Arigoni, M Bernasconi, D Christoforidis, M Di Giuseppe, D La Regina, F Mongelli, M Chevallay, O Dwidar, E Gialamas, M Sauvain, F Klenke, A Kollàr, C Kurze, M Adamina, T Bächler, A S Crugnale, M Giardini, L Guglielmetti, G Peros, F Solimene, A Aghayeva, I Hamzaoglu, I Sahin, E Akaydin, Z Aliyeva, E Aytac, B Baca, O DÜlgeroğlu, V Ozben, B B Ozmen, C Uras, A E Arikan, I A Bilgin, B Bozkirli, G O Ceyhan, H Kara, T Karahasanoglu, C Uras, H Celik, M M Meydanli, H Akilli, A Ayhan, E Kuscu, M A Onan, U Akgor, H A Dincer, T Erol, M Gultekin, N Orhan, N Ozgul, M C Salman, B Soyak, A Alhamed, S ErgÜn, M F OZcelik, A N Sanli, S S Uludag, M Velidedeoglu, A K Zengin, M A Bozkurt, Y Kara, A Kocatas, B Cimenoglu, R Demirhan, K Saracoglu, I F Azamat, E Balik, D Bugra, B Giray, C B Kulle, C Taskiran, D Vatansever, K Gözal, S A GÜler, H Köken, O C Tatar, N Z Utkan, A Yildirim, E YÜksel, E Akin, F Altintoprak, Z Bayhan, G Cakmak, R Çapoglu, F Çelebi, H Demir, E Dikicier, N Firat, E GönÜllÜ, M B Kamburoglu, B Kocer, I F KÜçÜk, B Mantoglu, E Çolak, G O Kucuk, M S Uyanik, B Göksoy, E Bozkurt, B Citgez, M Mihmanli, M Tanal, G Yetkin, M Akalin, C Arican, E K Avci, C Aydin, S Demirli Atici, M Emiroglu, T Kaya, E Kebabçi, G Kilinc, Y Kirmizi, H Ogucu, S Salimoglu, I Sert, C Tugmen, K Tuncer, G Uslu, D Yesilyurt, E Karaman, A Kolusari, A Yildiz, O Benson, H Lule, J Agilinko, A Ahmeidat, M Barabasz, M Bekheit, L K Cheung, T Colloc, W Cymes, M Elhusseini, G Gradinariu, A Hannah, B S Kamera, G Mignot, S Shaikh, P Sharma, I Abu-Nayla, A Agrawal, A Al-Mohammad, S Ali, J Ashcroft, A Azizi, O Baker, A Balakrishnan, M Byrne, A Colquhoun, A Cotter, P Coughlin, R J Davies, A Durrani, M Elshaer, S Fordington, P Forouhi, F Georgiades, H Grimes, A Habeeb, V Hudson, P Hutchinson, E Irune, A Jah, D Z Khan, A Kolias, H Kyriacou, B Lamb, S Liau, L Luke, R Mahmoud, R Mannion, L Masterson, C G Mitrofan, M Mohan, A Morris, S Murphy, R O'Neill, S Price, J Pushpa-Rajah, W Raby-Smith, J Ramzi, S Rooney, T Santarius, A Singh, G D Stewart, X S Tan, A Townson, E Tweedle, C Walker, S Waseem, S Yordanov, T Jones, A Kattakayam, C Loh, R Lunevicius, S Pringle, A Schache, R Shaw, A Sheel, C Rossborough, D Angelou, M Choynowski, B McAree, A McCanny, D Neely, G Tutoveanu, S Ahad, Mfi De La Cruz Monroy, F Mosley, V Oktseloglou, A Alanbuki, M Patel, A Shabana, E Perera, D Raveendran, K Ravi-Shankar, J Thiruchelvam, L Arrowsmith, W Campbell, T Grove, C Kontovounisios, O Warren, P Rolland, A Aggarwal, S Brown, C Jelley, N Neal, R Clifford, N Eardley, E Krishnan, N Manu, E Martin, S Roy Mahapatra, O L Serevina, C Smith, D Vimalachandran, M Bordenave, R Houston, G Putnam, A Robson, H Tustin, K Emslie, P L Labib, A Marchbank, D Miller, G Minto, J Natale, H Nwinee, P Panahi, L Rogers, A Abubakar, M M Akhter Rahman, E Chan, Kyk Ko, H O'Brien, K Sasapu, H Woodun, R Inglis, H J Ng, A De Gea Rico, N Ghazali, J Lambert, G Markose, S Math, I Sarantitis, D Shrestha, A Sultana, M Taggarsi, S Timbrell, O P Vaz, L Vitone, A Day, H Dent, M Fahim, S Waheed, A Hunt, N Laskar, A Gupta, J Steinke, S Thrumurthy, E Massie, K McGivern, D Rutherford, M Wilson, J Hardie, S Kazzaz, S Handa, M Kaushal, A Kler, P Patel, J Redfern, S Tezas, Y Aawsaj, S Amonkar, C Barry, L Blackwell, D Blake, J Carter, H Emerson, A Fisher, M Katory, P Korompelis, W McCormick, A Mustafa, L Pearce, N Ratnavelu, R Reehal, L Kretzmer, L Lalou, B Manku, I Parwaiz, J Stafford, M Abdelkarim, A Asqalan, T Gala, S Ibrahim, A Maw, R Mithany, R Morgan, G Sundaram Venkatesan, K Ang, E J Caruana, M F Chowdhry, A Mohammad, A Nakas, S Rathinam, M Boal, O Brown, S Dwerryhouse, S Higgs, A Vallance, E Boyd, V Irvine, A Kirk, G Bakolas, A Boulton, A Chandock, T Khan, M Kumar, P Agoston, A Bille, B Challacombe, S Fraser, K Harrison-Phipps, J King, G Mehra, L Mills, M Najdy, R Nath, L Okiror, J Pilling, V Rizzo, T Routledge, A Sayasneh, L Stroman, A Wali, M Fehervari, C Fotopoulou, N Habib, S Hamrang-Yousefi, Z Jawad, L Jiao, M Pai, J Ploski, P Rajagopal, S Saso, M Sodergren, D Spalding, S Laws, C Hardie, C McNaught, R Alam, A Budacan, J Cahill, M Kalkat, S Karandikar, L Kenyon, D Naumann, A Patel, J Ayorinde, T Chase, T Cuming, A Ghanbari, L Humphreys, S Tayeh, A Aboelkassem Ibrahim, R Bichoo, H Cao, Akw Chai, J Choudhury, C Evans, H Fitzjohn, H Ikram, M Langstroth, M Loubani, A McMillan, S Nazir, Ssa Qadri, A Robinson, E Ross, T Sehgal, A Wilkins, J Dixon, J Dunning, K Freystaetter, M Jha, S Lester, A Madhavan, S V Thulasiraman, Y Viswanath, T Curl-Roper, C Delimpalta, Ccl Liao, V Velchuru, E Westwood, E Belcher, G Bond-Smith, S Chidambaram, F Di Chiara, K Fasanmade, L Fraser, H Fu, M Ganau, S Gore, J Graystone, D Jeyaretna, H Khatkar, M Lami, M Maher, S Mastoridis, R Mihai, R Piper, S Prabhu, Obf Risk, U Selbong, K Shah, R Smillie, H Soleymani Majd, S Sravanam, D Stavroulias, G D Tebala, M Vatish, C Verberne, K Wallwork, S Winter, M I Bhatti, H Boyd-Carson, E Elsey, E Gemmill, P Herrod, M Jibreel, E Lenzi, T Saafan, D Sapre, T Sian, N Watson, A Athanasiou, G Bourke, L Bradshaw, A Brunelli, J Burke, P Coe, F Costigan, H Elkadi, M Ho, J Johnstone, A Kanatas, V Kantola, A Kaufmann, A Laios, S Lam, E MacInnes, S Munot, C Nahm, M Otify, C Pompili, I Smith, G Theophilou, G Toogood, R Wade, D Ward, C West, S Annamalai, C Ashmore, A Boddy, T Hossain, A Kourdouli, A Gvaramadze, A Jibril, L Prusty, D Thekkinkattil, A Harky, M Shackcloth, A Askari, C Chan, N Cirocchi, S Kudchadkar, K Patel, J Sagar, S Shaw, R Talwar, M Abdalla, R Edmondson, O Ismail, D Jones, K Newton, N Stylianides, A Aderombi, U Andaleeb, O Bajomo, K Beatson, W Garrett, M Mehmood, V Ng, R Al-Habsi, G S Divya, B Keeler, B Al-Sarireh, R Egan, R Harries, A Henry, M Kittur, Z Li, K Parkins, F Soliman, N Spencer, D Thompson, C Burgess, C Gemmell, C Grieco, M Hollyman, L Hunt, J Morrison, S Ojha, N Ryan, F Abbadessa, S Barnard, C Chan, N Dawe, J Hammond, Ali F Mahmoud, I McPherson, C Mellor, J Moir, S Pandanaboyana, J Powell, B Rai, A Rogers, C Roy, A Sachdeva, C Saleh, S Tingle, T Williams, J Manickavasagam, C McDonald, N McGrath, N McSorley, K Ragupathy, L Ramsay, A Solth, O Kakisi, K Seebah, I Shaikh, L Sreedharan, M Youssef, J Shah, P Ameerally, N McLarty, S Mills, A Shenfine, K Sahnan, J Abu, E Addae-Boateng, D Bratt, L Brock, N Burnside, S Cadwell-Sneath, K Gajjar, C Gan, C Grundy, K Hallam, K Hassell, M Hawari, A Joshi, H Khout, K Konstantinidi, Rxn Lee, D Nunns, R Schiemer, T Walton, H Weaver, L Whisker, K Williamson, J McVeigh, R Myatt, M A Williams, R Kaur, E Leung, S Sundar, M Michel, S Patil, S Ravindran, J Sarveswaran, L Scott, M Edmond, E King, M Almond, A Bhangu, O Breik, L D Cato, A Desai, S Ford, E Griffiths, M Idle, M Kamal, A Kisiel, R Kulkarni, Jkc Mak, T Martin, P Nankivell, A Parente, S Parmar, A M Pathanki, L Phelan, P Praveen, S Saeed, N Sharma, J Singh, F Tirotta, D Vijayan, A Geddes, J McCaul, J McMahon, A H Khan, F Khan, A Mansuri, S Mukherjee, M Patel, M Sarigul, S Singh, K L Tan, A Woodham, A Adiamah, H Brewer, A Chowdhury, J Evans, D Humes, J Jackman, A Koh, C Lewis-Lloyd, O Oyende, J Reilly, D Worku, P Cool, G Cribb, K Shepherd, C Bisset, S Moug, N Elson, G Faulkner, P Saleh, C Underwood, G Brixton, L Findlay, T Klatte, A Majkowska, J Manson, R Potter, A Bhalla, Z Chia, P Daliya, A Goyal, E Grimley, A Hamad, A Kumar, F L Malcolm, E Theophilidou, J Bowden, N Campain, I Daniels, C Evans, G Fowler, J John, L Massey, F McDermott, J McGrath, A McLennan, M Ng, J Pascoe, N Rajaretnam, S Bulathsinhala, B Davidson, G Fusai, C Hidalgo Salinas, N Machairas, T Pissanou, J M Pollok, D A Raptis, F Soggiu, H Tzerbinis, S E Xyda, A Beamish, E Davies, R Foulkes, D Magowan, H Nassa, R Ooi, C Price, L Smith, F Solari, A Tang, G Williams, Y Al-Tamimi, A Bacon, N Beasley, D Chew, M Crank, N Ilenkovan, M Macdonald, B Narice, O Rominiyi, A Thompson, I Varley, T Drake, E Harrison, G Linder, J Mayes, R McGregor, R Skipworth, V Zamvar, E Davies, P Hawkin, T Raymond, O Ryska, R Baron, D Dunne, S Gahunia, C Halloran, N Howes, R McKinney, F McNicol, J Russ, P Szatmary, J R Tan, A Thomas, P Whelan, A Anzak, A Banerjee, O Fuwa, F Hughes, J D Jayasinghe, C Knowles, H Kocher, I Leal Silva, F S Ledesma, A Minicozzi, L Navaratne, R Rahman, R Ramamoorthy, C Sohrabi, M Thaha, B Thakur, M Venn, V Yip, R Baumber, J Parry, S Evans, L Jeys, G Morris, M Parry, J Stevenson, N Ahmadi, G Aresu, Z M Barrett-Brown, A S Coonar, H Durio Yates, D Gearon, J Hogan, M King, A Peryt, I S Pradeep, C Smith, M Adishesh, R Atherton, K Baxter, M Brocklehurst, M Chaudhury, N Krishnamohan, J McAleer, G Owens, E Parkin, P Patkar, I Phang, A Aladeojebi, M Ali, B Barmayehvar, A Gaunt, M Gowda, E Halliday, M Kitchen, F Mansour, M Thomas, D Zakai, N Abbassi-Ghadi, H Assalaarachchi, A Currie, M Flavin, A Frampton, M Hague, C Hammer, J Hopper, J Horsnell, S Humphries, A Kamocka, T K Madhuri, S Preston, P Singh, J Stebbing, A Tailor, D Walker, F Aljanadi, M Jones, P Mhandu, C O'Donnell, R Turkington, Z Al-Ishaq, S Bhasin, A S Bodla, A Burahee, A Crichton, R Fossett, N Pigadas, S Pickford, E Rahman, D Snee, R Vidya, N Yassin, F Colombo, D Fountain, M T Hasan, K Karabatsou, R Laurente, O Pathmanaban, A Al-Mukhtar, S Brown, J Edwards, A Giblin, C Kelty, M Lee, G Lye, T Newman, A Sharkey, C Steele, N Sureshkumar Shah, E Whitehall, R Athwal, A Baker, L Jones, C Konstantinou, S Ramcharan, S Singh, J Vatish, R Wilkin, M Ethunandan, G K Sekhon, H Shields, R Singh, F Wensley, S Lawday, A Lyons, T Abbott, S Anwar, K Ghufoor, C Sohrabi, E Chung, R Hagger, A Hainsworth, A Karim, H Owen, A Ramwell, K Williams, C Baker, A Davies, J Gossage, M Kelly, W Knight, J Hall, G Harris, G James, C Kang, D J Lin, A D Rajgor, T Royle, R Scurrah, B Steel, L J Watson, D Choi, R Hutchison, A Jain, V Luoma, H Marcus, R May, A Menon, B Pramodana, L Webber, I A Aneke, P Asaad, B Brown, J Collis, S Duff, A Khan, F Moura, B Wadham, H Warburton, T Elmoslemany, M Jenkinson, C Millward, R Zakaria, S Mccluney, C Parmar, S Shah, J Allison, M S Babar, B Collard, S Goodrum, K Lau, A Patel, R Scott, E Thomas, H Whitmore, D Balasubramaniam, B Jayasankar, S Kapoor, A Ramachandran, A Elhamshary, Smb Imam, K Kapriniotis, V Kasivisvanathan, J Lindsay, S Rakhshani-Moghadam, N Beech, M Chand, L Green, N Kalavrezos, H Kiconco, R McEwen, C Schilling, D Sinha, J Pereca, J Singh, S Chopra, D Egbeare, R Thomas, T Combellack, Sef Jones, M Kornaszewska, M Mohammed, A Sharma, G Tahhan, V Valtzoglou, J Williams, P Eskander, K Gash, L Gourbault, M Hanna, T Maccabe, C Newton, J Olivier, S Rozwadowski, E Teh, D West, H Al-Omishy, M Baig, H Bates, G Di Taranto, K Dickson, N Dunne, C Gill, D Howe, D Jeevan, A Khajuria, K Martin-Ucar AMcEvoy, P Naredla, V Ng, S Robertson, M Sait, D R Sarma, S Shanbhag, T Shortland, S Simmonds, J Skillman, N Tewari, G Walton, M A Akhtar, A Brunt, J McIntyre, K Milne, M M Rashid, A Sgro, K E Stewart, A Turnbull, M Aguilar Gonzalez, S Talukder, C Boyle, D Fernando, K Gallagher, A Laird, D Tham, M Bath, P Patki, C Sohrabi, C Tanabalan, T Arif, C Magee, T Nambirajan, S Powell, R Vinayagam, I Flindall, A Hanson, V Mahendran, S Green, M Lim, L MacDonald, V Miu, L Onos, K Sheridan, R Young, F Alam, O Griffiths, C Houlden, R Jones, V S Kolli, A K Lala, S Leeson, R Peevor, Z Seymour, L Chen, E Henderson, A Loehrer, K Brown, D Fleming, A Haynes, C Heron, C Hill, H Kay, E Leede, K McElhinney, K Olson, E C Osterberg, C Riley, P Srikanth, M Thornhill, D Blazer, G DiLalla, E S Hwang, W Lee, M Lidsky, J Plichta, L Rosenberger, R Scheri, K Shah, K Turnage, J Visgauss, S Zani, J Farma, J Clark, D Kwon, E Etchill, H E Gabre-Kidan AJenny, A Kent, M Ladd, C Long, H Malapati, A Margalit, S Rapaport, J Rose, K Stevens, L Tsai, D Vervoort, P Yesantharao, A Dehal, D Klaristenfeld, K Huynh, L Brown, I Ganly, J Mullinax, N Gusani, J Hazelton, J Maines, J S Oh, A Ssentongo, P Ssentongo, M Azam, A Choudhry, W Marx, J Fleming, A Fuson, J Gigliotti, A Ovaitt, Y Ying, M K Abel, V Andaya, K Bigay, M A Boeck, L Chen, H Chern, C Corvera, I El-Sayed, A Glencer, P Ha, Bcs Hamilton, C Heaton, K Hirose, D M Jablons, K Kirkwood, L Z Kornblith, J R Kratz, R Lee, P N Miller, E Nakakura, B Nunez-Garcia, R O'Donnell, D Ozgediz, P Park, B Robinson, A Sarin, B Sheu, M Varma, K Wai, R Wustrack, M J Xu, D Beswick, J Goddard, J Manor, J Song, T Fullmer, C Gaskill, N Gross, K Kiong, C L Roland, S N Zafar, M Abdallah, A Abouassi, M Almasri, G Kulkarni, H Marwan, M Mehdi, S Aoun, V S Ban, H H Batjer, J Caruso, D Abbott, A Acher, T Aiken, J Barrett, E Foley, P Schwartz, S N Zafar, A Hawkins, A Maiga, J Laufer, S Scasso
- Subjects
Aged, 80 and over ,Male ,Critical Care ,SARS-CoV-2 ,International Cooperation ,COVID-19 ,Middle Aged ,Cohort Studies ,Logistic Models ,Postoperative Complications ,Elective Surgical Procedures ,Neoplasms ,Outcome Assessment, Health Care ,Humans ,Female ,Epidemics ,Aged - Abstract
PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks.
- Published
- 2021
5. P-237 Esophageal microbiome correlates with post-esophagectomy anastomotic leak in cancer patients
- Author
-
Naddaf, R., Shmilovich, H., Carasso, S., Kashtan, H., Markaer, S., Nilsson, M., Goshen-Lago, T., Geffen, T., Geva-Zatorsky, N., and Ben-Aharon, I.
- Published
- 2023
- Full Text
- View/download PDF
6. Procleave: Predicting Protease-specific Substrate Cleavage Sites by Combining Sequence and Structural Information
- Author
-
Li, F, Leier, A, Liu, Q, Wang, Y, Xiang, D, Akutsu, T, Webb, G, Smith, AI, Marquez-Lago, T, Li, J, Song, J, Li, F, Leier, A, Liu, Q, Wang, Y, Xiang, D, Akutsu, T, Webb, G, Smith, AI, Marquez-Lago, T, Li, J, and Song, J
- Abstract
Proteases are enzymes that cleave and hydrolyse the peptide bonds between two specific amino acid residues of target substrate proteins. Protease-controlled proteolysis plays a key role in the degradation and recycling of proteins, which is essential for various physiological processes. Thus, solving the substrate identification problem will have important implications for the precise understanding of functions and physiological roles of proteases, as well as for therapeutic target identification and pharmaceutical applicability. Consequently, there is a great demand for bioinformatics methods that can predict novel substrate cleavage events with high accuracy by utilizing both sequence and structural information. In this study, we present Procleave, a novel bioinformatics approach for predicting protease-specific substrates and specific cleavage sites by taking into account both their sequence and 3D structural information. Structural features of known cleavage sites were represented by discrete values using a LOWESS data-smoothing optimization method, which turned out to be critical for the performance of Procleave. The optimal approximations of all structural parameter values were encoded in a conditional random field (CRF) computational framework, alongside sequence and chemical group-based features. Here, we demonstrate the outstanding performance of Procleave through extensive benchmarking and independent tests. Procleave is capable of correctly identifying most cleavage sites in the case study. Importantly, when applied to the human structural proteome encompassing 17,628 protein structures, Procleave suggests a number of potential novel target substrates and their corresponding cleavage sites of different proteases. Procleave is implemented as a webserver and is freely accessible at http://procleave.erc.monash.edu/.
- Published
- 2020
7. Stochastic jump behavior in heterogeneous media: SW06.W30–33
- Author
-
Marquez-Lago, T. T., Leier, A., and Burrage, K.
- Published
- 2013
8. Reduction of chemical reaction networks with distributed delays: SW06.W30–35
- Author
-
Leier, A., Marquez-Lago, T. T., and Barrio, M.
- Published
- 2013
9. A selection criterion for patterns in reactiondiffusion systems: SW06.W30–34
- Author
-
Marquez-Lago, T. T. and Padilla, P.
- Published
- 2013
10. Simulating diffusion in crowded environments with multifractional Brownian motion: P24-20
- Author
-
Leier, A., Marquez-Lago, T. T., and Burrage, K.
- Published
- 2012
11. Envelope morphology in nuclear compartmentalization and asymmetric segregation of nucleoplasmic factors during yeast closed mitosis: P24-8
- Author
-
Marquez-Lago, T., Boettcher, B., Bayer, M., and Barral, Y.
- Published
- 2012
12. Maternal morbidity and near miss in the community: findings from the 2006 Brazilian demographic health survey
- Author
-
Souza, J P, Cecatti, J G, Parpinelli, M A, Sousa, M H, Lago, T G, Pacagnella, R C, and Camargo, R S
- Published
- 2010
- Full Text
- View/download PDF
13. Young-onset gastric cancer: The role of microbial factors
- Author
-
Ben-Aharon, I., primary, Moore, A., additional, Hikri, E., additional, Goshen-Lago, T., additional, Lazar, T., additional, Kashtan, H., additional, and Brenner, B., additional
- Published
- 2017
- Full Text
- View/download PDF
14. 645P - Young-onset gastric cancer: The role of microbial factors
- Author
-
Ben-Aharon, I., Moore, A., Hikri, E., Goshen-Lago, T., Lazar, T., Kashtan, H., and Brenner, B.
- Published
- 2017
- Full Text
- View/download PDF
15. On Objectives of Instructional Laboratories, Individual Assessment, and Use of Collaborative Remote Laboratories
- Author
-
Gustavsson, I., primary, Nilsson, K., additional, Zackrisson, J., additional, Garcia-Zubia, J., additional, Hernandez-Jayo, U., additional, Nafalski, A., additional, Nedic, Z., additional, Gol, O., additional, Machotka, J., additional, Pettersson, M.I., additional, Lago, T., additional, and Hkansson, L., additional
- Published
- 2009
- Full Text
- View/download PDF
16. A New Passive/Active Hybrid Headset for a Helicopter Application
- Author
-
Winberg, M., primary, Johansson, S., additional, Lago, T., additional, and Claesson, I., additional
- Published
- 1999
- Full Text
- View/download PDF
17. Erratum: Infant feeding and risk of mother-to-child transmission of HIV- 1 in Sao Paulo State, Brazil (Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (1998) 19 (189-194))
- Author
-
BEATRIZ HELENA TESS, Rodrigues, L. C., Newell, M. -L, Dunn, D. T., and Lago, T. D. G.
18. Prediction of secondary structure population and intrinsic disorder of proteins using multitask deep learning
- Author
-
Ying, X., Leier, A., Marquez-Lago, T. T., Jue Xie, Jimeno Yepes, A. J., Whisstock, J. C., Wilson, C., and Song, J.
- Subjects
Intrinsically Disordered Proteins ,Deep Learning ,Articles ,Protein Structure, Secondary - Abstract
Recent research in predicting protein secondary structure populations (SSP) based on Nuclear Magnetic Resonance (NMR) chemical shifts has helped quantitatively characterise the structural conformational properties of intrinsically disordered proteins and regions (IDP/IDR). Different from protein secondary structure (SS) prediction, the SSP prediction assumes a dynamic assignment of secondary structures that seem correlate with disordered states. In this study, we designed a single-task deep learning framework to predict IDP/IDR and SSP respectively; and multitask deep learning frameworks to allow quantitative predictions of IDP/IDR evidenced by the simultaneously predicted SSP. According to independent test results, single-task deep learning models improve the prediction performance of shallow models for SSP and IDP/IDR. Also, the prediction performance was further improved for IDP/IDR prediction when SSP prediction was simultaneously predicted in multitask models. With p53 as a use case, we demonstrate how predicted SSP is used to explain the IDP/IDR predictions for each functional region.
19. O Programa de Humanização no Pré-natal e Nascimento do Ministério da Saúde no Brasil: resultados iniciais
- Author
-
Serruya Suzanne Jacob, Cecatti José Guilherme, and Lago Tania di Giacomo do
- Subjects
Saúde Materno-infantil ,Saúde da Mulher ,Avaliação de Programas ,Maternal and Child Health ,Women's Health ,Program Evaluation ,Medicine ,Public aspects of medicine ,RA1-1270 - Abstract
Avalia-se a experiência da implantação do Programa de Humanização no Pré-natal e Nascimento do Ministério da Saúde, no Brasil, a partir dos dados gerados pelo SISPRENATAL/DATASUS. De sua instituição em junho de 2000 até dezembro de 2002, 3.983 municípios aderiram, e 71% desses (3.183) registraram procedimentos no âmbito do programa, constituindo um banco de dados com 720.871 mulheres. Cerca de 20% das mulheres realizaram seis ou mais consultas de pré-natal, e cerca da metade delas realizou também a consulta puerperal e os exames obrigatórios em 2002, e 41% das mulheres foram imunizadas com a vacina antitetânica. A realização de exames para a detecção de HIV foi o dobro em relação à sífilis, nos dois anos em análise. O conjunto das atividades assistenciais recomendado foi recebido apenas por um pequeno percentual de mulheres, 2% em 2001 e 5% em 2002. Os baixos percentuais registrados ratificam a necessidade de permanentes avaliações com o objetivo de melhorar a qualidade dessa atenção, garantindo, além de melhores resultados maternos e perinatais, o direito inalienável de cada mulher de gestar e parir com segurança e bem-estar.
- Published
- 2004
20. O diafragma como método contraceptivo: a experiência de usuárias de serviços públicos de saúde
- Author
-
Kalckmann Suzana, Lago Tania Giacomo do, Barbosa Regina Maria, Villela Wilza, and Goihman Samuel
- Subjects
Diafragma ,Planejamento Familiar ,Anticoncepcionais ,Medicine ,Public aspects of medicine ,RA1-1270 - Abstract
Este estudo objetiva descrever como o diafragma foi incorporado ao cotidiano de 194 mulheres que o escolheram como contraceptivo, em cinco serviços públicos da região de Osasco, Grande São Paulo, no período de agosto de 1989 a agosto de 1991. O seguimento dessa coorte foi realizado por meio de entrevistas domiciliares semestrais. Constatou-se que o diafragma pode ser uma escolha viável, pois as mulheres, mesmo as de baixa renda, interessam-se por inovações que possam representar alternativas às suas práticas contraceptivas. No entanto, a taxa acumulada de continuidade de uso aos 12 meses foi de 25,7%; após 365 dias, 39 mulheres mantiveram o seu uso contínuo. Do total de mulheres que escolheram o diafragma, 37,1% referiram usá-lo em todas as relações durante o período de observação. Os resultados mostram a necessidade de os serviços readequarem a atividade de planejamento familiar, no sentido de dar um maior suporte às mulheres que optaram pelo diafragma, envolvendo seus parceiros nesta tomada de decisão. Além disso, a equipe de planejamento familiar da unidade também precisaria de um reforço contínuo visando aprimorar as técnicas de medição e o apoio à mulher frente as suas dificuldades iniciais com o método.
- Published
- 1997
21. The Symmiktos method: a robust and accurate estimation method for acoustic Doppler current estimation.
- Author
-
Lago, T., Eriksson, P., and Asman, M.
- Published
- 1993
- Full Text
- View/download PDF
22. Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial.
- Author
-
Lago T, Peixoto F, Mambelli F, Carvalho LP, Guimarães LH, Carvalho AM, Cardoso L, Machado PRL, Scott P, Lago J, Andrade JM, Fahel JS, Oliveira SC, and Carvalho EM
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Young Adult, Treatment Outcome, Meglumine administration & dosage, Meglumine therapeutic use, Adolescent, Animals, Leishmania braziliensis drug effects, Administration, Intravenous, Granzymes metabolism, Leishmaniasis, Cutaneous drug therapy, Leishmaniasis, Cutaneous parasitology, Meglumine Antimoniate therapeutic use, Meglumine Antimoniate administration & dosage, Antiprotozoal Agents therapeutic use, Antiprotozoal Agents administration & dosage, Administration, Topical, Drug Therapy, Combination, Organometallic Compounds therapeutic use, Organometallic Compounds administration & dosage
- Abstract
Background: Cutaneous leishmaniasis (CL) caused by Leishmania (Viannia) braziliensis is associated with an inflammatory response. Granzyme (GzmB) and IL-1β play a key role in the pathology. Meglumine antimoniate (MA) is the first-choice drug for the treatment of CL, but therapy failure is observed in up to 50% of the cases. The protein, rSm29 of Schistosoma mansoni, down-modulates pro-inflammatory cytokine production. We evaluate if the combination of topical rSm29 plus MA increases the cure rate of CL., Methods: In this randomized clinical trial, 91 CL patients were allocated in 3 groups. All cases received MA (20 mg/kg/weight) for 20 days. Group 1 used topical rSm29 (10 µg), group 2 a placebo topically applied, and group 3 received only MA., Results: The cure rate on day 90 was 71% in subjects treated with rSm29 plus MA, and 43% in patients who received MA plus placebo or MA alone (P < 0.05). There was a decrease in GzmB and an increase in IFN-γ (P < 0.05) in supernatants of skin biopsies of the lesions obtained on D7 of therapy (P < 0.05) in patients who received rSm29., Conclusion: rSm29 associated with MA reduces GzmB levels, is more effective than MA alone, and decreases CL healing time., Clinical Trials Registration: ClinicalTrial.gov under NCT06000514., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions.
- Author
-
Borba PB, Lago J, Lago T, Araújo-Pereira M, Queiroz ATL, Barud HS, Carvalho LP, Machado PRL, Carvalho EM, and de Oliveira CI
- Abstract
Leishmaniasis, caused by Leishmania parasites, is a neglected tropical disease and Cutaneous Leishmaniasis (CL) is the most common form. Despite the associated toxicity and adverse effects, Meglumine antimoniate (MA) remains the first-choice treatment for CL in Brazil, pressing the need for the development of better alternatives. Bacterial NanoCellulose (BNC), a biocompatible nanomaterial, has unique properties regarding wound healing. In a previous study, we showed that use of topical BNC + systemic MA significantly increased the cure rate of CL patients, compared to treatment with MA alone. Herein, we performed a study comparing the combination of a wound dressing (BNC or placebo) plus systemic MA versus systemic MA alone, in CL caused by Leishmania braziliensis . We show that patients treated with the combination treatment (BNC or placebo) + MA showed improved cure rates and decreased need for rescue treatment, although differences compared to controls (systemic MA alone) were not significant. However, the overall time-to-cure was significantly lower in groups treated with the combination treatment (BNC+ systemic MA or placebo + systemic MA) in comparison to controls (MA alone), indicating that the use of a wound dressing improves CL treatment outcome. Assessment of the immune response in peripheral blood showed an overall downmodulation in the inflammatory landscape and a significant decrease in the production of IL-1a ( p < 0.05) in patients treated with topical BNC + systemic MA. Our results show that the application of wound dressings to CL lesions can improve chemotherapy outcome in CL caused by L. braziliensis .
- Published
- 2024
- Full Text
- View/download PDF
24. MicroRNAs correlate with bacillary index and genes associated to cell death processes in leprosy.
- Author
-
de Lima Santana N, Neves de Farias L, Lago T, Leal-Calvo T, Lima Machado PR, and Castellucci LC
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Leprosy microbiology, Leprosy pathology, Leprosy genetics, Skin microbiology, Skin pathology, Apoptosis genetics, Cell Death, Young Adult, Aged, Erythema Nodosum microbiology, Erythema Nodosum genetics, Erythema Nodosum pathology, Autophagy genetics, MicroRNAs genetics, MicroRNAs metabolism, Mycobacterium leprae genetics
- Abstract
Mycobacterium leprae infects skin and peripheral nerves causing a broad of clinical forms. MicroRNAs (miRNAs) control immune mechanisms such as apoptosis, autophagy as well as to target genes leading to abnormal proliferation, metastasis, and invasion of cells. Herein we evaluated miRNAs expression for leprosy phenotypes in biopsies obtained from patients with and without reactions. We also correlated those miRNAs with both, bacillary index (BI) and genes involved in the micobacteria elimination process. Our results show a significant increase in the miR-125a-3p expression in paucibacillary (PB) patients vs multibacillary (MB) subjects (p = 0.007) and vs reversal reactions (RR) (p = 0.005), respectively. Likewise, there was a higher expression of miR-125a-3p in patients with erythema nodosum leprosum (ENL) vs MB without reactions (p = 0.002). Furthermore, there was a positive correlation between miR-125a-3p, miR-146b-5p and miR-132-5p expression and BI in patients with RR and ENL. These miRNAS were also correlated with genes such as ATG12 (miR-125a-3p), TNFRSF10A (miR-146b-5p), PARK2, CFLAR and STX7 (miR-132-5p). All together we underpin a role for these miRNAs in leprosy pathogenesis, implicating mechanisms such as apoptosis and autophagy in skin. The miR-125a-3p might have a distinct role associated with PB phenotype and ENL in MB patients., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
- Author
-
Machado PRL, Lago A, Cardoso TM, Magalhaes A, Carvalho LP, Lago T, Carvalho AM, Costa R, and Carvalho EM
- Subjects
- Humans, Meglumine Antimoniate therapeutic use, Leishmania braziliensis, Leishmaniasis, Cutaneous diagnosis, Leishmaniasis, Cutaneous drug therapy, Leishmania, Phosphorylcholine analogs & derivatives
- Abstract
Disseminated leishmaniasis (DL) is an emergent severe disease manifesting with multiple lesions. To determine the relationship between immune response and clinical and therapeutic outcomes, we studied 101 DL and 101 cutaneous leishmaniasis (CL) cases and determined cytokines and chemokines in supernatants of mononuclear cells stimulated with leishmania antigen. Patients were treated with meglumine antimoniate (20 mg/kg) for 20 days (CL) or 30 days (DL); 19 DL patients were instead treated with amphotericin B, miltefosine, or miltefosine and meglumine antimoniate. High levels of chemokine ligand 9 were associated with more severe DL. The cure rate for meglumine antimoniate was low for both DL (44%) and CL (60%), but healing time was longer in DL (p = 0.003). The lowest cure rate (22%) was found in DL patients with >100 lesions. However, meglumine antimoniate/miltefosine treatment cured all DL patients who received it; therefore, that combination should be considered as first choice therapy.
- Published
- 2024
- Full Text
- View/download PDF
26. Short communication: The miR-155a-5p is correlated with increased ROS and impaired apoptosis in macrophages infected by Leishmania braziliensis.
- Author
-
Lago T, Cardoso TM, Rocha A, Carvalho EM, and Castellucci LC
- Subjects
- Humans, Reactive Oxygen Species metabolism, Macrophages metabolism, Apoptosis genetics, Leishmania braziliensis physiology, Leishmaniasis, Cutaneous parasitology, MicroRNAs genetics
- Abstract
Cutaneous leishmaniasis (CL) caused by Leishmania braziliensis, is a disease characterized by well-limited ulcerated lesions with raised borders in exposed parts of the body. miRNAs are recognized for their role in the complex and plastic interaction between host and pathogens, either as part of the host's strategy to neutralize infection or as a molecular mechanism employed by the pathogen to modulate host inflammatory pathways to remain undetected. The mir155 targets a broad range of inflammatory mediators, following toll-like receptors (TLRs) signaling. In this work, we evaluated the effects of the expression of miR155a-5p in human macrophages infected with L. braziliensis. Our results show that miR155a-5p is inversely correlated with early apoptosis and conversely, seems to influence an increment in the oxidative burst in these cells. Altogether, we spotted a functional role of the miR155a-5p in CL pathogenesis, raising the hypothesis that an increased miR-155 expression by TLR ligands influences cellular mechanisms settled to promote both killing and control of parasite density after infection., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Lago et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
27. Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study.
- Author
-
Ben-Aharon I, Rotem R, Melzer-Cohen C, Twig G, Cercek A, Half E, Goshen-Lago T, Chodik G, and Kelsen D
- Subjects
- Young Adult, Humans, Adolescent, Case-Control Studies, Bayes Theorem, Anti-Bacterial Agents, Inflammatory Bowel Diseases, Colorectal Neoplasms drug therapy, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics
- Abstract
Background: The incidence of early-onset colorectal cancer (EOCRC) rose abruptly in the mid 1990s, is continuing to increase, and has now been noted in many countries. By 2030, 25% of American patients diagnosed with rectal cancer will be 49 years or younger. The large majority of EOCRC cases are not found in patients with germline cancer susceptibility mutations (eg, Lynch syndrome) or inflammatory bowel disease. Thus, environmental or lifestyle factors are suspected drivers. Obesity, sedentary lifestyle, diabetes mellitus, smoking, alcohol, or antibiotics affecting the gut microbiome have been proposed. However, these factors, which have been present since the 1950s, have not yet been conclusively linked to the abrupt increase in EOCRC. The sharp increase suggests the introduction of a new risk factor for young people. We hypothesized that the driver may be an off-target effect of a pharmaceutical agent (ie, one requiring regulatory approval before its use in the general population or an off-label use of a previously approved agent) in a genetically susceptible subgroup of young adults. If a pharmaceutical agent is an EOCRC driving factor, regulatory risk mitigation strategies could be used., Objective: We aimed to evaluate the possibility that pharmaceutical agents serve as risk factors for EOCRC., Methods: We conducted a case-control study. Data including demographics, comorbidities, and complete medication dispensing history were obtained from the electronic medical records database of Maccabi Healthcare Services, a state-mandated health provider covering 26% of the Israeli population. The participants included 941 patients with EOCRC (≤50 years of age) diagnosed during 2001-2019 who were density matched at a ratio of 1:10 with 9410 control patients. Patients with inflammatory bowel disease and those with a known inherited cancer susceptibility syndrome were excluded. An advanced machine learning algorithm based on gradient boosted decision trees coupled with Bayesian model optimization and repeated data sampling was used to sort through the very high-dimensional drug dispensing data to identify specific medication groups that were consistently linked with EOCRC while allowing for synergistic or antagonistic interactions between medications. Odds ratios for the identified medication classes were obtained from a conditional logistic regression model., Results: Out of more than 800 medication classes, we identified several classes that were consistently associated with EOCRC risk across independently trained models. Interactions between medication groups did not seem to substantially affect the risk. In our analysis, drug groups that were consistently positively associated with EOCRC included beta blockers and valerian (Valeriana officinalis). Antibiotics were not consistently associated with EOCRC risk., Conclusions: Our analysis suggests that the development of EOCRC may be correlated with prior use of specific medications. Additional analyses should be used to validate the results. The mechanism of action inducing EOCRC by candidate pharmaceutical agents will then need to be determined., (©Irit Ben-Aharon, Ran Rotem, Cheli Melzer-Cohen, Gilad Twig, Andrea Cercek, Elizabeth Half, Tal Goshen-Lago, Gabriel Chodik, David Kelsen. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 13.12.2023.)
- Published
- 2023
- Full Text
- View/download PDF
28. MicroRNAs regulating macrophages infected with Leishmania L. ( V. ) Braziliensis isolated from different clinical forms of American tegumentary leishmaniasis.
- Author
-
Lago T, Medina L, Lago J, Santana N, Cardoso T, Rocha A, Leal-Calvo T, Carvalho EM, and Castellucci LC
- Subjects
- Humans, United States, Macrophages metabolism, Skin, MicroRNAs genetics, MicroRNAs metabolism, Leishmania, Leishmaniasis, Cutaneous
- Abstract
Background: Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania . There are still no vaccines, and therapeutic options are limited, indicating the constant need to understand the fine mechanisms of its pathophysiology. An approach that has been explored in leishmaniasis is the participation of microRNAs (miRNAs), a class of small non-coding RNAs that act, in most cases, to repress gene expression. miRNAs play a role in the complex and plastic interaction between the host and pathogens, either as part of the host's immune response to neutralize infection or as a molecular strategy employed by the pathogen to modulate host pathways to its own benefit., Methods: Monocyte-derived macrophages from healthy subjects were infected with isolates of three clinical forms of L. braziliensis : cutaneous (CL), mucosal (ML), and disseminated (DL) leishmaniasis. We compared the expression of miRNAs that take part in the TLR/NFkB pathways. Correlations with parasite load as well as immune parameters were analyzed., Results: miRNAs -103a-3p, -21-3p, 125a-3p -155-5p, -146a-5p, -132- 5p, and -147a were differentially expressed in the metastatic ML and DL forms, and there was a direct correlation between miRNAs -103a-3p, -21-3p, -155-5p, -146a-5p, -132-5p, and -9-3p and parasite load with ML and DL isolates. We also found a correlation between the expression of miR-21-3p and miR-146a-5p with the antiapoptotic gene BCL2 and the increase of viable cells, whereas miR-147a was indirectly correlated with CXCL-9 levels., Conclusion: The expression of miRNAs is strongly correlated with the parasite load and the inflammatory response, suggesting the participation of these molecules in the pathogenesis of the different clinical forms of L. braziliensis ., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lago, Medina, Lago, Santana, Cardoso, Rocha, Leal-Calvo, Carvalho and Castellucci.)
- Published
- 2023
- Full Text
- View/download PDF
29. A Modified Technique of Percutaneous Fixation of Displaced Pediatric Lateral Humeral Condyle Elbow Fractures (aka the Martini Technique): A Brief Case Series.
- Author
-
Hodo TW, Suwak P, Lago T, Ramos T, and Accousti W
- Subjects
- Child, Humans, Humerus, Retrospective Studies, Bone Nails, Elbow Fractures, Elbow Joint surgery, Humeral Fractures surgery, Fracture Fixation instrumentation, Fracture Fixation methods
- Abstract
Displaced lateral humeral condyle (LHC) fractures have routinely been treated with open reduction, which has known postoperative complications. Recent reports show that closed reduction and percutaneous pinning (CRPP) is a valid treatment. Five pediatric patients with displaced LHC fractures were included in a retrospective case series. Closed reductions (CRs) were facilitated by Kirschner wire placement into the capitellum through a toothed drill guide. The Kirschner wire and drill guide were used like a joystick to manipulate the fragment and maintain reduction for placement of additional Kirschner wires. Patient records were used to determine the number of patients diagnosed with LHC fractures between 2011 to 2022 among six pediatric orthopaedic surgeons at one institution along with the treatment and associated complications. Satisfactory reduction of displaced LHC fractures was achieved with CRPP in all patients with no complications using the "martini" modification. Of 26 LHC fractures, 16 were treated with CRPP/CRPS and 10 with open reduction and percutaneous pinning/open reduction and internal fixation, with four converted from CR to OR. Complications included one superficial infection in the CR group and four stiff elbows and one nonunion in the OR group option for LHC fractures. CRPP is an effective treatment option with a decreased risk of complications. Our modified reduction technique may help improve the success and results of closed treatment of LHC fractures., (Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons.)
- Published
- 2023
- Full Text
- View/download PDF
30. Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
- Author
-
Lago J, Fraga D, Guimarães LH, Lago T, Silva YJ, Lago E, Werneck GL, Bacellar O, and Carvalho EM
- Abstract
[This corrects the article DOI: 10.1371/journal.pntd.0011064.]., (Copyright: © 2023 Lago et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
31. Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
- Author
-
Lago J, Fraga D, Guimarães LH, Lago T, Silva YJ, Lago E, Werneck GL, Bacellar O, and Carvalho EM
- Subjects
- Humans, Dogs, Animals, Meglumine Antimoniate therapeutic use, Meglumine therapeutic use, Saline Solution therapeutic use, Ulcer drug therapy, Antiprotozoal Agents therapeutic use, Leishmaniasis, Cutaneous pathology, Organometallic Compounds therapeutic use, Leishmania braziliensis
- Abstract
Dogs living in areas of Leishmania (Viannia) braziliensis transmission may present canine tegumentary leishmaniasis (CTL) characterized by cutaneous or muzzle ulcers as well as asymptomatic L. braziliensis infection. It is not clear if dogs participate in the transmission chain of L. braziliensis to humans. However, dogs may remain with chronic ulcers for a long time, and as there are no public policies about CTL, these animals die or are sacrificed. Here we compare the efficacy of intralesional meglumine antimoniate with intralesional 0.9% NaCl solution in CTL treatment. This randomized control study included 32 dogs with cutaneous or muzzle lesions who had L. braziliensis DNA detected by PCR in tissue biopsied. Group one received 5ml of intralesional Glucantime, and group two received 5ml 0.9% NaCl solution, both applied in the four cardinal points on days 0, 15, and 30. Cure was defined as complete healing of the ulcers in the absence of raised borders on day 90. There was no difference in animals' demographic and clinical features in the two groups (p >.05). While at the endpoint, the cure rate was 87.5% in the group test, and in those who received 0.9 NaCl the cure rate was only 12.5%. As important as the high cure rate, the healing time was faster in dogs treated with antimony than in those treated with saline (p < .001). Intralesional meglumine antimoniate is effective in the treatment of dogs with L. braziliensis infection and accelerates the healing time of CTL., Competing Interests: We declare that there is no relationship or support which might be perceived as constituting a conflict of interest., (Copyright: © 2023 Lago et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
32. Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.
- Author
-
Waldhorn I, Holland R, Goshen-Lago T, Benguigui M, Halberthal M, Shaked Y, and Ben-Aharon I
- Subjects
- BNT162 Vaccine, Humans, Neoplasms, Vaccines
- Published
- 2022
- Full Text
- View/download PDF
33. Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID-19) crisis: An observational longitudinal study.
- Author
-
Turgeman I, Goshen-Lago T, Waldhorn I, Karov K, Groisman L, Reiner Benaim A, Almog R, Halberthal M, and Ben-Aharon I
- Subjects
- Depression epidemiology, Depression etiology, Depression psychology, Female, Humans, Longitudinal Studies, Pandemics, SARS-CoV-2, Breast Neoplasms epidemiology, Breast Neoplasms therapy, COVID-19 epidemiology
- Abstract
Background: The coronavirus disease 2019 (COVID-19) crisis and consequent changes in medical practice have engendered feelings of distress in diverse populations, potentially adversely affecting the psychological well-being of cancer patients., Aim: The purpose of this observational longitudinal study was to evaluate psychosocial perspectives among patients with cancer on intravenous treatment during the COVID-19 pandemic., Methods and Results: The study recruited 164 cancer patients undergoing intravenous anti-neoplastic therapy in a tertiary cancer center. Psychosocial indices were assessed at two points in time, corresponding with the beginning of the first wave of COVID-19 pandemic in Israel (March 2020) and the time of easing of restrictions implemented to curtail spread of infection (May 2020). At Time 1 (T1), elevated COVID-19 distress levels (score 1 and 2 on 5-point scale) were observed in 44% of patients, and associated with pre-existing hypertension and lung disease in multivariate analyses but no demographic or cancer related factors. At Time 2 (T2), 10% had elevated anxiety and 24% depression as indicated by Hospital Anxiety and Depression Scale (HADS-A/D). COVID-19 distress at T1 was related to higher levels of HADS-A at T2 (Spearman 0.33 p < .01), but not HADS-D. Patients with breast cancer expressed greater COVID-19 distress compared with other cancer types (p < .01), while both HADS-A and HADS-D were highest for patients with GI cancer. Patient report of loneliness and decreased support from relatives were factors associated with HADS-A (p = .03 and p < .01, respectively), while HADS-D was not similarly related to the factors evaluated., Conclusion: Patients with cancer undergoing intravenous treatment may be vulnerable to acute adverse psychological ramifications of COVID-19, specifically exhibiting high levels of anxiety. These appear unrelated to patient age or disease stage. Those with underlying comorbidities, breast cancer or reduced social support may be at higher risk., (© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
34. Tumor Lymphocyte Infiltration Is Correlated with a Favorable Tumor Regression Grade after Neoadjuvant Treatment for Esophageal Adenocarcinoma.
- Author
-
Haddad R, Zlotnik O, Goshen-Lago T, Levi M, Brook E, Brenner B, Kundel Y, Ben-Aharon I, and Kashtan H
- Abstract
(1) Background: We aimed to explore the association between neoadjuvant treatment, tumor-infiltrating immune lymphocyte (TIL), and tumor-associated macrophage (TAM) and survival in patients with esophageal adenocarcinoma. (2) Methods: Patients who underwent esophagectomy were divided into three groups according to their treatment modality and tumor regression grade (TRG): (i) surgery-only group (SG), (ii) good responders (GR) group (TRG 0−1), and (iii) bad responders (BR) group (TRG 2−3). We then carried out statistical correlations of the immunofluorescence analysis of the immune infiltrate in the esophageal surgical specimens with several clinical and pathological parameters. In addition, we analyzed The Cancer Genomic Atlas (TCGA) dataset for differences in TILs, TAMs, and protein expression in immune pathways. (3) Results: Forty-three patients (SG—15, GR—13, and BR—13) were evaluated. The highest enrichment of CD3+ (p < 0.001), CD8+ (p = 0.001) and CD4+ (p = 0.009) was observed in the stroma of GR patients. On multivariate analysis, only CD8+ T cell and signet-ring features were independent prognostic factors for overall survival. In TCGA analysis, we identified overexpression of TAM and colony-stimulating factor 1 receptor (CSF-1R). (4) Conclusions: High enrichment of lymphocyte subpopulations in the microenvironment of esophageal adenocarcinoma is associated with a favorable response to neoadjuvant treatment and an improved patient outcome.
- Published
- 2022
- Full Text
- View/download PDF
35. Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer.
- Author
-
Zlotnik O, Goshen-Lago T, Haddad R, Brenner B, Kundel Y, Ben-Aharon I, and Kashtan H
- Subjects
- Biomarkers, Humans, Middle Aged, Neoadjuvant Therapy methods, Proteomics, Adenocarcinoma drug therapy, Esophageal Neoplasms therapy, Stomach Neoplasms
- Abstract
Background: Esophageal cancer represents a global challenge. Despite significant evolution of treatment protocols in the past decade, recurrence rates are still high and survival rates are poor. Current treatment paradigm for localized gastroesophageal junction (GEJ) carcinoma remains to be further elucidated as for the role of neoadjuvant chemoradiation versus perioperative chemotherapy., Aim: To identify biomarkers for response to chemoradiation in esophageal and gastroesophageal cancer, we performed an in-depth proteomic analysis of esophageal and gastroesophageal tumors, to describe differences in pathway activation between patients with favorable and poor prognosis following neoadjuvant chemoradiation., Methods: Patients with locally advanced esophageal and gastroesophageal cancer following neoadjuvant chemoradiation were included in the cohort. The study cohort was dichotomized into two groups of patients, named "favorable prognosis" and "poor prognosis" according to the postoperative disease-free interval. We performed a mass spectrometry analysis of proteins extracted from the malignant regions of surgical specimens and analyzed data from electronic medical records. Clinical data was correlated with differences in protein expression between patient with a favorable and poor prognosis using validated gene expression pathways., Results: The study included 35 patients with adenocarcinoma. All patients in this cohort had esophageal adenocarcinoma. Patients median age was 62 years. Twenty-five (71.3%) patients underwent neoadjuvant chemoradiation, and 28.7% underwent neoadjuvant chemotherapy only. A proteomic analysis of our cohort identified 2885 proteins. Enrichment levels of 98 of these proteins differed significantly between favorable and poor prognosis cohorts in patients who underwent neoadjuvant chemoradiation (p < .05) but not in patients who underwent neoadjuvant chemotherapy. The favorable prognosis patients group analysis exhibited differential enrichment of 87 proteins related to cellular respiration and oxidative phosphorylation pathways as well as proteins of the RAS oncogene family., Conclusion: In this study we identified differential enrichment of pathways related to oxidative phosphorylation and RAS oncogene pathway in esophageal cancer patients with a favorable response to chemoradiation. Following further validation, our findings may portray potential surrogate signature of biomarkers based upon these pathways., (© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
36. Systematic Characterization of Lysine Post-translational Modification Sites Using MUscADEL.
- Author
-
Chen Z, Liu X, Li F, Li C, Marquez-Lago T, Leier A, Webb GI, Xu D, Akutsu T, and Song J
- Subjects
- Amino Acid Sequence, Animals, Machine Learning, Mice, Proteome metabolism, Lysine metabolism, Protein Processing, Post-Translational
- Abstract
Among various types of protein post-translational modifications (PTMs), lysine PTMs play an important role in regulating a wide range of functions and biological processes. Due to the generation and accumulation of enormous amount of protein sequence data by ongoing whole-genome sequencing projects, systematic identification of different types of lysine PTM substrates and their specific PTM sites in the entire proteome is increasingly important and has therefore received much attention. Accordingly, a variety of computational methods for lysine PTM identification have been developed based on the combination of various handcrafted sequence features and machine-learning techniques. In this chapter, we first briefly review existing computational methods for lysine PTM identification and then introduce a recently developed deep learning-based method, termed MUscADEL (Multiple Scalable Accurate Deep Learner for lysine PTMs). Specifically, MUscADEL employs bidirectional long short-term memory (BiLSTM) recurrent neural networks and is capable of predicting eight major types of lysine PTMs in both the human and mouse proteomes. The web server of MUscADEL is publicly available at http://muscadel.erc.monash.edu/ for the research community to use., (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
37. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
- Author
-
Machado PRL, Prates FVO, Boaventura V, Lago T, Guimarães LH, Schriefer A, Corte TWF, Penna G, Barral A, Barral-Netto M, and Carvalho EM
- Subjects
- Antimony therapeutic use, Brazil, Granulocyte-Macrophage Colony-Stimulating Factor, Granulocytes, Humans, Macrophage Colony-Stimulating Factor therapeutic use, Phosphorylcholine analogs & derivatives, Treatment Outcome, Antiprotozoal Agents therapeutic use, Leishmania braziliensis, Leishmaniasis, Cutaneous drug therapy
- Abstract
Background: The treatment of cutaneous leishmaniasis (CL) in Brazil using pentavalent antimony (Sbv) is associated with a high rate of failure. Miltefosine has proven efficacy for CL caused by L. braziliensis, with a cure rate (CR) of 75%. A combined treatment with granulocyte macrophage colony-stimulating factor (GM-CSF) and miltefosine could increase CR and decrease healing time., Methods: A randomized, double-blind clinical trial to evaluate the efficacy of miltefosine combined with topical GM-CSF (M + GM) vs miltefosine and placebo (M + P) vs Sbv in 133 patients with CL caused by L. braziliensis in Bahia, Brazil., Results: The final CR at 180 days after the initiation of treatment was 44.4% in the Sbv group, 76.6% in the M + P group (P = .003 vs Sbv), and 75.6% in the M + GM group (P = .004 vs Sbv). The median healing time for cure was 102 days for the Sbv group and 60 days for both miltefosine groups (P = .0009). During the 6-month follow-up period, 4 relapses were documented: 1 in the Sbv group, 1 in the M + P group, and 2 in the M + GM group. Mild adverse events occurred in 65% of patients from the Sbv group, 76% and 79% from the M + P and M + GM groups respectively., Conclusions: Miltefosine is more effective than Sbv for the treatment of CL caused by L. braziliensis in Brazil and accelerates the healing time. Association with GM-CSF does not improve therapeutic outcome., Clinical Trials Registration: NCT03023111., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
38. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
- Author
-
Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, Reiter Y, Almog R, Halberthal M, and Ben-Aharon I
- Subjects
- Adult, Aged, Aged, 80 and over, BNT162 Vaccine, COVID-19 Vaccines adverse effects, Case-Control Studies, Humans, Immunoglobulin G blood, Israel, Male, Middle Aged, Neoplasms blood, Neoplasms immunology, Prospective Studies, Seroconversion, Tertiary Care Centers, Treatment Outcome, Antibodies, Viral blood, Antineoplastic Agents therapeutic use, COVID-19 Vaccines immunology, Neoplasms drug therapy
- Abstract
Importance: The efficacy and safety profile of SARS-CoV-2 vaccines have been acquired from phase 3 studies; however, patients with cancer were not represented in these trials. Owing to the recommendation to prioritize high-risk populations for vaccination, further data are warranted., Objective: To evaluate the use and safety of the BNT162b2 vaccine in patients undergoing treatment for cancer., Design, Setting, and Participants: In January 2021, mass SARS-CoV-2 vaccination of high-risk populations, including patients with cancer, was initiated in Israel. This cohort study prospectively enrolled and followed up patients with cancer and healthy participants between January 15 and March 14, 2021. The study was conducted at the Division of Oncology of Rambam Health Care Campus, the major tertiary (referral) medical center of northern Israel. Participants included 232 patients with cancer who were receiving active treatment after the first and second doses of the BNT162b2 vaccine and 261 healthy, age-matched health care workers who served as controls., Exposures: Serum samples were collected after each vaccine dose and in cases of seronegativity. Questionnaires regarding sociodemographic characteristics and adverse reactions were administered at serum collection. A regulatory agencies-approved assay was used to assess IgG at all time points. Patients' electronic medical records were reviewed for documentation of COVID-19 infection and results of blood cell counts, liver enzyme levels, and imaging studies., Main Outcomes and Measures: Seroconversion rate after the first and second doses of the BNT162b2 vaccine and documented COVID-19 infection., Results: Of the 232 patients undergoing treatment for cancer, 132 were men (57%); mean (SD) age was 66 (12.09) years. After the first dose of BNT162b2 vaccine, 29% (n = 25) patients were seropositive compared with 84% (n = 220) of the controls (P < .001). After the second dose, the seropositive rate reached 86% (n = 187) in the patients. Testing rate ratios per 1000 person-days after the first dose were 12.5 (95% CI, 3.4-45.7) for the patients and 48.5 (95% CI, 37.2-63.2) for the controls. Patients undergoing chemotherapy showed reduced immunogenicity (odds ratio, 0.41; 95% CI, 0.17-0.98). In seronegative patients, the rate of documented absolute leukopenia reached 39%. No COVID-19 cases were documented throughout the study period; however, 2 cases in the patient cohort were noted immediately after the first dose. Reported adverse events were similar to data in former trials comprising mostly healthy individuals., Conclusions and Relevance: In this cohort study, the SARS-CoV-2 BNT162b2 vaccine appeared to be safe and achieve satisfactory serologic status in patients with cancer. There was a pronounced lag in antibody production compared with the rate in noncancer controls; however, seroconversion occurred in most patients after the second dose. Future real-world data are warranted to determine the long-term efficacy of the vaccine with regard to type of anticancer treatment.
- Published
- 2021
- Full Text
- View/download PDF
39. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors.
- Author
-
Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Peer A, Almog R, Shaked Y, Halberthal M, and Ben-Aharon I
- Subjects
- Adult, Aged, Aged, 80 and over, BNT162 Vaccine, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, Health Personnel, Humans, Male, Middle Aged, Neutropenia chemically induced, Thrombocytopenia chemically induced, Time-to-Treatment, Vaccination, COVID-19 Vaccines adverse effects, COVID-19 Vaccines pharmacology, Neoplasms drug therapy
- Abstract
We had previously reported short-term efficacy, immunogenicity, and safety of the BNT162b2 vaccine among cancer patients with solid tumors. We aimed to evaluate these outcomes at six months postvaccination. The study cohort comprised patients who were on treatment during vaccination and throughout six months postvaccination. Serologic tests were performed after second vaccination and six months afterward. An age-matched cohort of health care workers served as controls. Documentation of COVID-19 infection, blood tests, and imaging studies during the study period was reviewed. Participants included 154 patients and 135 controls. Six months postvaccination, 122 (79%) patients were seropositive compared with 114 (84%) controls ( P = 0.32). Serology titer dramatically decreased in a similar manner in both cohorts. No COVID-19 cases were documented in controls, and one case occurred in patient cohort. All previously reported adverse effects resolved. Taken together, the pattern of immunogenicity, efficacy, and safety of BNT162b2 in patients with cancer with solid tumors at six months postvaccination resembles that of the general population. SIGNIFICANCE: Evidence regarding efficacy and safety of COVID-19 vaccines in patients with cancer indicate a favorable short-term profile. Immunomodulation due to anticancer treatments may affect immunity and immunogenicity of patients with cancer to the BNT162b2 vaccine over time. Our study sheds light on these long-term outcomes and portrays a trend that resembles the general population. This article is highlighted in the In This Issue feature, p. 2355 ., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
40. Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.
- Author
-
Lago T, Carvalho LP, Nascimento M, Guimarães LH, Lago J, Castellucci L, Carvalho AM, Lago A, and Carvalho EM
- Subjects
- Humans, Meglumine Antimoniate therapeutic use, Obesity complications, Antiprotozoal Agents therapeutic use, Leishmania braziliensis, Leishmaniasis, Cutaneous drug therapy
- Abstract
Background: Cutaneous leishmaniasis (CL) caused by Leishmania braziliensis is characterized by a single ulcer or multiple cutaneous lesions with raised borders. Cure rates <60% are observed in response to meglumine antimoniate therapy. We investigated the impact of obesity on CL clinical presentation and therapeutic response., Methods: A total of 90 age-matched patients with CL were included (30 obese, 30 overweight, and 30 with normal body mass index [BMI]). CL was diagnosed through documentation of L. braziliensis DNA by polymerase chain reaction or identification of amastigotes in biopsied skin-lesion samples. Serum cytokine levels were determined by chemiluminescence. Antimony therapy with Glucantime (Sanofi-Aventis; 20 mg/kg/day) was administered for 20 days., Results: Obese CL patients may present hypertrophic ulcers rather than typical oval, ulcerated lesions. A direct correlation between BMI and healing time was noted. After 1 course of antimony, cure was achieved in 73% of patients with normal BMI, 37% of overweight subjects, yet just 18% of obese CL patients (P < .01). Obese CL cases additionally presented higher leptin levels than overweight patients or those with normal BMI (P < .05)., Conclusions: Obesity modifies the clinical presentation of CL and host immune response and is associated with greater failure to therapy., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
41. Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia.
- Author
-
Elitzur S, Frank S, Goshen-Lago T, Barzilai-Birenboim S, Gilad G, Avrahami G, Goldberg T, Litichever N, Masarwa A, Oron G, Yaniv I, Izraeli S, and Ben-Aharon I
- Subjects
- Adult, Anti-Mullerian Hormone, Child, Female, Fertility, Humans, Survivors, Ovarian Reserve, Precursor Cell Lymphoblastic Leukemia-Lymphoma epidemiology
- Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, yet data regarding long-term ovarian reserve of female survivors are limited. The aim of this study was to investigate whether there is a differential pattern of anti-Mullerian hormone (AMH) levels in female childhood ALL survivors compared with the normal age-matched population. In a cohort of 56 female childhood ALL survivors (median age 29 years; median follow-up 20.6 years), a negative correlation was found between age at leukemia diagnosis and age-adjusted anti-Mullerian hormone (AMH) levels ( r = -0.334, p = .031). Despite alkylating agent therapy, AMH levels did not differ significantly from age-related nomograms (age < 30, p = .17; age ≥ 30, p = .94). The mean number of children per fertile woman adjusted for maternal age was similar to the national average (2.76 versus 3.11, p = .19). Our results imply that reproductive outcomes are not significantly hampered in female pediatric ALL survivors. Long-term surveillance of ovarian reserve may enable personalized survivorship counseling.
- Published
- 2021
- Full Text
- View/download PDF
42. Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles.
- Author
-
Grunberg N, Pevsner-Fischer M, Goshen-Lago T, Diment J, Stein Y, Lavon H, Mayer S, Levi-Galibov O, Friedman G, Ofir-Birin Y, Syu LJ, Migliore C, Shimoni E, Stemmer SM, Brenner B, Dlugosz AA, Lyden D, Regev-Rudzki N, Ben-Aharon I, and Scherz-Shouval R
- Subjects
- Animals, Cancer-Associated Fibroblasts pathology, Cells, Cultured, Cohort Studies, Disease Progression, Extracellular Vesicles pathology, Heat Shock Transcription Factors genetics, Humans, Mice, Mice, 129 Strain, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Invasiveness, Phenotype, Prognosis, Secretory Pathway physiology, Stomach Neoplasms diagnosis, Stomach Neoplasms metabolism, Stomach Neoplasms mortality, Survival Analysis, Tumor Microenvironment physiology, Cancer-Associated Fibroblasts physiology, Extracellular Vesicles metabolism, Heat Shock Transcription Factors metabolism, Stomach Neoplasms pathology
- Abstract
Gastric cancer is the third most lethal cancer worldwide, and evaluation of the genomic status of gastric cancer cells has not translated into effective prognostic or therapeutic strategies. We therefore hypothesize that outcomes may depend on the tumor microenvironment (TME), in particular, cancer-associated fibroblasts (CAF). However, very little is known about the role of CAFs in gastric cancer. To address this, we mapped the transcriptional landscape of human gastric cancer stroma by microdissection and RNA sequencing of CAFs from patients with gastric cancer. A stromal gene signature was associated with poor disease outcome, and the transcription factor heat shock factor 1 (HSF1) regulated the signature. HSF1 upregulated inhibin subunit beta A and thrombospondin 2, which were secreted in CAF-derived extracellular vesicles to the TME to promote cancer. Together, our work provides the first transcriptional map of human gastric cancer stroma and highlights HSF1 and its transcriptional targets as potential diagnostic and therapeutic targets in the genomically stable tumor microenvironment. SIGNIFICANCE: This study shows how HSF1 regulates a stromal transcriptional program associated with aggressive gastric cancer and identifies multiple proteins within this program as candidates for therapeutic intervention. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/7/1639/F1.large.jpg., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
43. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.
- Author
-
Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, Brenner B, and Ben-Aharon I
- Subjects
- Bile Ducts, Intrahepatic, Humans, Mutation, Receptor, ErbB-2 genetics, Signal Transduction, Trastuzumab, Bile Duct Neoplasms drug therapy, Bile Duct Neoplasms genetics, Cholangiocarcinoma drug therapy, Cholangiocarcinoma genetics, Gastrointestinal Neoplasms
- Abstract
Background/aims: Current chemotherapy regimens for cholangiocarcinoma (CCA) yield poor outcomes, with a median overall survival of <12 months. Recent data on the genomic landscape of CCAs have created opportunities for targeted therapy. Yet, data regarding its efficacy are scarce. We aimed to describe the genomic landscape of a CCA patient cohort using next-generation sequencing (NGS), focusing on the ERBB/EFGR pathway and assessing response to anti-HER2 agents., Methods: Tissue samples of intrahepatic CCA (IHCC) and extrahepatic CCA (EHCC) underwent NGS for somatic aberrations. The clinical outcomes for patients treated with anti-HER2 agents were evaluated., Results: A total of 1,863 CCA cases (1,615 IHCCs and 248 EHCCs) underwent NGS, and they revealed a high prevalence of ERBB alterations (IHCC, 4.2%; EHCC, 9.7%). Among these, 23.8% of the IHCCs and 53.6% of the EHCCs had a point mutation in ERBB2, and 66.6% of the IHCCs and 41.2% of the EHCCs had ERBB copy number amplification. Three EHCC patients were diagnosed at our institute with ERBB/EGFR aberrations; 2 patients were treated with neratinib and 1 patient with a chemotherapy-trastuzumab combination. All 3 achieved disease stabilization and a clinical benefit. One patient underwent a liquid biopsy before and after 3 months of treatment, demonstrating disappearance of the ERBB2 clone and emergence of a Myc-mutated clone after treatment., Conclusions: The genomic landscape of CCAs may harbor targetable alterations, especially in the ERBB/EGFR pathway. These alterations may have clinical significance in everyday practice., (© 2020 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
44. Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity-From Bench to Bedside.
- Author
-
Levi M, Goshen-Lago T, Yerushalmi R, Granot T, Stemmer SM, Shalgi R, and Ben-Aharon I
- Abstract
Background: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2/neu) antibody, is considered a standard treatment in addition to chemotherapy in the adjuvant setting for HER2/neu-positive breast cancer, yet its impact on fertility and ovarian reserve remains obscure. We aimed to study the effect of anti-HER2/neu on chemotherapy-induced ovarian toxicity in both clinical and preclinical settings., Methods: We prospectively enrolled breast cancer patients below the age of 42 years who were treated with chemotherapy with or without trastuzumab into the study. Anti-Müllerian hormone (AMH) was measured 6 and 12 months post-chemotherapy as an ovarian reserve indicator. In the animal model, pubertal mice were injected with cyclophosphamide or paclitaxel with or without anti-HER2/neu, or saline, and sacrificed 1 week or 3 months later. Ovarian apoptosis, proliferation and vascularity were measured by immunohistochemistry and ovarian reserve was measured by morphometric analysis and serum-AMH., Results: Thirty-three patients with early breast cancer were enrolled into the study. Nineteen patients had HER2/neu negative cancer and were treated with chemotherapy and 14 had HER2/neu positive cancer and were treated with chemotherapy and trastuzumab. In all patients, AMH levels declined to undetectable values immediately post-treatment, but regained for 57.1% of the HER2/neu positive cohort and 36.8% of the negative cohort ( p < 0.05). In the preclinical setting, anti-HER2/neu antibody, in combination with chemotherapy, displayed lessened ovarian and vascular damage., Conclusions: Our results indicate that trastuzumab may alleviate chemotherapy-induced ovarian toxicity that may be mediated via its effect on ovarian vasculature.
- Published
- 2020
- Full Text
- View/download PDF
45. The Potential Role of Immune Alteration in the Cancer-COVID19 Equation-A Prospective Longitudinal Study.
- Author
-
Goshen-Lago T, Szwarcwort-Cohen M, Benguigui M, Almog R, Turgeman I, Zaltzman N, Halberthal M, Shaked Y, and Ben-Aharon I
- Abstract
Background: The risk of cancer patients to develop COVID19 infection is unclear. We aimed to prospectively study cancer patients and oncology healthcare workers for COVID19 serology. In IgG+ cases, immune profile was determined to portray the pattern of immune response to SARS-CoV2. Methods: Cancer patients on active treatment and healthcare workers were enrolled. During the study period (3/2020-6/2020), demographic data and blood were collected at three time points. Expression of IgG, IgM, and IgA were assessed. In SARS-CoV-2 IgG+ cases and matched negative cases, we performed mass cytometry time of flight (CyTOF) analysis on the basis of the expression of surface markers. Results: The study included 164 cancer patients on active intravenous treatment and 107 healthcare workers at the cancer center. No symptomatic cases were reported during the study period. Serology analysis revealed four IgG+ patients (2.4%) and two IgG+ healthcare workers (1.9%)-all were asymptomatic. CyTOF analysis demonstrated substantial reduction in myeloid cells in healthcare workers who were SARS-CoV-2 IgG+ compared to those who were SARS-CoV-2 IgG-, whereas in cancer patients, the reduction was relatively milder (≈50% reduction in SARS-CoV-2 IgG+ cancer patients compared with ≈90% reduction in SARS-CoV-2 IgG+ workers). Conclusion: Our results indicate a similar rate of asymptomatic COVID19 infection in cancer patients and healthcare workers in a longitudinal study throughout the pandemic time. Due to differential immune cell profiles of cancer patients who are treated with immunomodulatory agents, the host response to the SARS-COV2 may play a role in COVID19 course and representation. The immunological perspective of cancer treatments on the risk for COVID19 infection should be further explored.
- Published
- 2020
- Full Text
- View/download PDF
46. Better cognitive efficiency is associated with increased experimental anxiety.
- Author
-
Grillon C, Lago T, Stahl S, Beale A, Balderston N, and Ernst M
- Subjects
- Adult, Blinking physiology, Electromyography, Female, Humans, Male, Reflex, Startle physiology, Young Adult, Anxiety physiopathology, Executive Function physiology, Memory, Short-Term physiology, Psychomotor Performance physiology
- Abstract
There is increased interest in the development of cognitive training targeting working memory (WM) to alleviate anxiety symptoms, but the effectiveness of such an approach is unclear. Improved understanding of the effect of cognitive training on anxiety may facilitate the development of more effective cognitive training treatment for anxiety disorders. This study uses an experimental approach to examine the interplay of WM and anxiety following WM training. Previous studies show that increased demand on WM reduces concurrent anxiety evoked by threat of shock (induced anxiety). However, improving WM pharmacologically or via exercise prevents this anxiolytic effect. Conceivably, improving WM frees up cognitive resources to process threat information, thereby increasing anxiety. The present study tested the hypothesis that practicing a high load WM (i.e., increased demand) task would improve WM, and thus, free cognitive resources to process threat of shock, resulting in more anxiety (i.e., greater startle) during a subsequent WM task. Participants were randomly assigned to two training groups. The active-training group (N = 20) was trained on a 1- (low load) & 3-back (high load) WM task, whereas the control-training group (N = 20) performed a 0-back WM task. The experimental phase, similar in both groups, consisted of a 1- & 3-back WM task performed during both threat of shock and safety. As predicted, active training improved WM accuracy and increased anxiety during the experimental 3-back WM task. Therefore, improving WM efficiency can increase anxiety, possibly by freeing WM resources to process threat information., (Published 2020. This article is a U.S. Government work and is in the public domain in the USA.)
- Published
- 2020
- Full Text
- View/download PDF
47. Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity.
- Author
-
Bar-Joseph H, Peccatori FA, Goshen-Lago T, Cribiù FM, Scarfone G, Miller I, Nemerovsky L, Levi M, Shalgi R, and Ben-Aharon I
- Abstract
Breast cancer is diagnosed in ~0.3% of pregnant women. Studies that have addressed gestational and neonatal outcomes of chemotherapy during pregnancy have demonstrated increased gestational complications including preeclampsia and intrauterine growth retardation. We hypothesized that anthracycline-induced gestational complications could be derived from direct toxicity on the placenta vasculature. Pregnant ICR mice (day E12.5) were treated with doxorubicin (DXR; 8 mg/kg) or saline, while their umbilical cord blood flow was imaged by pulse-wave (PW) Doppler. Mice were euthanized on day E18.5, and their embryos and placentae were collected for further analysis. Unlike control mice, the DXR-treated mice presented an acute change in the umbilical cord's blood flow parameters (velocity time integral and heart rate interval), reduced embryos' weight, reduced placenta efficiency, and modulation in vascular-related pathways of treated placenta proteomics. Apoptosis and proliferation were also enhanced, as demonstrated by TUNEL and proliferating cell nuclear antigen (PCNA) analysis. We further examined the placentae of patients treated with epirubicin (EPI), who had been diagnosed with breast cancer during pregnancy (weeks 27-35). The immunohistochemistry of the EPI-treated human placentae showed enhanced proliferation and apoptosis as compared with matched chemo-naïve placentae, as well as reduced neovascularization (CD34). Our findings suggest that anthracycline-induced vascular insult promotes placental toxicity, and could point to potential agents designated to offset the damage and to reduce gestational complications in pregnant cancer patients., Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2020
- Full Text
- View/download PDF
48. Young patients with cancer and a digital social network: the voice beyond the clinic.
- Author
-
Ben-Aharon I, Goshen-Lago T, Turgeman I, Fontana E, Smyth E, and Lordick F
- Subjects
- Adolescent, Adult, Ecosystem, Humans, Middle Aged, Social Networking, Surveys and Questionnaires, Survivors, Young Adult, Cancer Survivors, Neoplasms
- Abstract
Introduction: Digital social networks have become a key player in the ecosystem of young patients with cancer, with regard to their unique perspectives and unmet needs. This study aims to investigate the web-based social community tools and to characterise the user profile, unmet needs and goals of young patients with cancer., Methods: A web-based survey was distributed via large-scale social network designated for young patients with cancer (age 18-45 years) Stop Cancer. The survey collected demographic data and oncological status. Primary outcome was potential goals of accessing the network; secondary outcomes were emotional impact, effect of disease status, education, marital status and employment, on user satisfaction rate., Results: The survey was available for 5 days (10/2018) and was filled by 523 participants. Breast cancer, haematological malignancies and colorectal cancer were the most common diagnoses. The majority had non-metastatic disease at diagnosis, 79% had no evidence of disease at time of the survey. Forty-five per cent considered the network as a reliable source for medical information. Academic education was associated with higher satisfaction from the platform. There were no differences between cancer survivors and patients with active disease in patterns of platform usage. The social network had an allocated section for 'patient mentoring' of newly diagnosed members by survivors., Discussion: Our study portrayed the user prototype of a social digital network among young adult patients with cancer, indicating challenging trends. Whereas social media may prove a powerful tool for patients and physicians alike, it may also serve as a research tool to appraise wide practices within a heterogeneous population. Nevertheless, it acts as a double-edged sword in the setting of uncontrolled medical information. It is our role as healthcare providers to join this race and play an active role in shaping its medical perspectives., Competing Interests: Competing interests: None declared., (© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2020
- Full Text
- View/download PDF
49. Mechanistic link between right prefrontal cortical activity and anxious arousal revealed using transcranial magnetic stimulation in healthy subjects.
- Author
-
Balderston NL, Beydler EM, Roberts C, Deng ZD, Radman T, Lago T, Luber B, Lisanby SH, Ernst M, and Grillon C
- Subjects
- Anxiety physiopathology, Anxiety prevention & control, Cross-Over Studies, Female, Healthy Volunteers, Humans, Magnetic Resonance Imaging methods, Male, Reflex, Startle physiology, Anxiety diagnostic imaging, Arousal physiology, Prefrontal Cortex diagnostic imaging, Prefrontal Cortex physiology, Transcranial Magnetic Stimulation methods
- Abstract
Much of the mechanistic research on anxiety focuses on subcortical structures such as the amygdala; however, less is known about the distributed cortical circuit that also contributes to anxiety expression. One way to learn about this circuit is to probe candidate regions using transcranial magnetic stimulation (TMS). In this study, we tested the involvement of the dorsolateral prefrontal cortex (dlPFC), in anxiety expression using 10 Hz repetitive TMS (rTMS). In a within-subject, crossover experiment, the study measured anxiety in healthy subjects before and after a session of 10 Hz rTMS to the right dorsolateral prefrontal cortex (dlPFC). It used threat of predictable and unpredictable shock to induce anxiety and anxiety potentiated startle to assess anxiety. Counter to our hypotheses, results showed an increase in anxiety-potentiated startle following active but not sham rTMS. These results suggest a mechanistic link between right dlPFC activity and physiological anxiety expression. This result supports current models of prefrontal asymmetry in affect, and lays the groundwork for further exploration into the cortical mechanisms mediating anxiety, which may lead to novel anxiety treatments.
- Published
- 2020
- Full Text
- View/download PDF
50. DeepCleave: a deep learning predictor for caspase and matrix metalloprotease substrates and cleavage sites.
- Author
-
Li F, Chen J, Leier A, Marquez-Lago T, Liu Q, Wang Y, Revote J, Smith AI, Akutsu T, Webb GI, Kurgan L, and Song J
- Subjects
- Caspases, Metalloproteases, Software, Substrate Specificity, Deep Learning
- Abstract
Motivation: Proteases are enzymes that cleave target substrate proteins by catalyzing the hydrolysis of peptide bonds between specific amino acids. While the functional proteolysis regulated by proteases plays a central role in the 'life and death' cellular processes, many of the corresponding substrates and their cleavage sites were not found yet. Availability of accurate predictors of the substrates and cleavage sites would facilitate understanding of proteases' functions and physiological roles. Deep learning is a promising approach for the development of accurate predictors of substrate cleavage events., Results: We propose DeepCleave, the first deep learning-based predictor of protease-specific substrates and cleavage sites. DeepCleave uses protein substrate sequence data as input and employs convolutional neural networks with transfer learning to train accurate predictive models. High predictive performance of our models stems from the use of high-quality cleavage site features extracted from the substrate sequences through the deep learning process, and the application of transfer learning, multiple kernels and attention layer in the design of the deep network. Empirical tests against several related state-of-the-art methods demonstrate that DeepCleave outperforms these methods in predicting caspase and matrix metalloprotease substrate-cleavage sites., Availability and Implementation: The DeepCleave webserver and source code are freely available at http://deepcleave.erc.monash.edu/., Supplementary Information: Supplementary data are available at Bioinformatics online., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.